Combined pharmaceutical composition of substituted 2-hydrogen-pyrazole derivative and use thereof
Patent Information
- Application Number
- MYPI2025004635
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-02-09
- Filing Date
- 2024-02-08
- Publication Date
- 2024-08-09
AI Technical Summary
In the current technology, for HR+ breast cancer patients with a high risk of recurrence, adjuvant endocrine therapy still needs to be optimized to further reduce the risk of breast cancer recurrence.
A combination pharmaceutical composition is provided, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and an endocrine therapy drug, such as an aromatase inhibitor, an estrogen receptor antagonist or a pituitary gonadotropin-releasing hormone analogue A combination for the treatment or prevention of breast cancer in patients who have undergone surgical treatment.
Through the use of combined pharmaceutical compositions, invasive cancer-free survival, distant recurrence-free survival and overall survival are significantly improved, adverse reactions are reduced, and better disease control rate and longer survival are provided.
Abstract
Description
Combined pharmaceutical composition of substituted 2-hydrogen-pyrazole derivatives and use thereof
[0001] Citation of Related Applications
[0002] This application claims priority and benefits of Chinese patent application No. 202310103670.5 filed with the State Intellectual Property Office of the People's Republic of China on February 9, 2023, the entire contents of which are hereby incorporated by reference into this document in their entirety. Technical Field
[0003] The present disclosure belongs to the field of medical technology, and relates to a combination pharmaceutical composition of substituted 2-hydrogen-pyrazole derivatives and uses thereof, and specifically relates to a combination pharmaceutical composition of a compound of formula (I) and uses thereof for treating breast cancer. Background Art
[0004] Cyclin-dependent kinase (CDK) 4 / 6 is a key regulator of the cell cycle, which can trigger the cell cycle to enter the DNA replication phase (S1 phase) from the growth phase (G1 phase). During cell proliferation, the complex formed by CDK4 / 6 and cyclin D (CyclinD) can phosphorylate the retinoblastoma protein (Rb). Once the tumor suppressor protein Rb is phosphorylated, it can release the transcription factor E2F to which it is tightly bound in the unphosphorylated state. E2F activates further transcription and promotes the cell cycle through the restriction point (R point) and progresses from the G1 phase to the S phase. Therefore, inhibiting CDK4 / 6 so that it cannot form a CyclinD-CDK4 / 6 complex can block the progression of the cell cycle from the G1 phase to the S phase, thereby achieving the purpose of inhibiting tumor proliferation. WO2016141881 discloses substituted 2-hydrogen-pyrazole derivatives as selective CDK4 / 6 inhibitors, and specifically discloses a compound of formula (I) having the following structure,
[0005] According to international and domestic guidelines and consensus, adjuvant endocrine therapy is currently recommended for patients with early-stage HR+ / HER2- breast cancer after surgery. For premenopausal patients, the recommended adjuvant endocrine therapy regimen is a 5-year ovarian function suppressant (OFS) combined with an aromatase inhibitor (AI) or tamoxifen (TAM), or a 5-year TAM monotherapy regimen. For postmenopausal patients, a 5-year aromatase inhibitor (AI) regimen is recommended as adjuvant endocrine therapy. For high-risk HR+ / HER2- early breast cancer patients, a 5-year AI ± OFS regimen is preferred. Due to the high accessibility and clinical efficacy of endocrine therapy, a meta-analysis showed that patients with HR+, node-negative low-risk breast cancer who received standard adjuvant endocrine therapy had a 43% relative recurrence risk reduction and a 15.6% absolute benefit over 10 years. However, for patients with HR+ breast cancer at high risk of recurrence, the currently recommended adjuvant endocrine therapy regimen still needs to be optimized, and more targeted treatment options are needed to further reduce the risk of recurrence in these patients.
[0006] Summary of the Invention
[0007] In one aspect, the present disclosure provides a combination pharmaceutical composition for treating or preventing breast cancer in patients who have undergone surgical treatment, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and an endocrine therapy drug,
[0008] In some embodiments of the present disclosure, the endocrine therapy drug is selected from one or two of an aromatase inhibitor, an estrogen receptor antagonist, or a pituitary gonadotropin-releasing hormone analogue. In some embodiments of the present disclosure, the endocrine therapy drug is selected from an aromatase inhibitor, an estrogen receptor antagonist, a pituitary gonadotropin-releasing hormone analogue, a combination of an aromatase inhibitor and a pituitary gonadotropin-releasing hormone analogue, or a combination of an estrogen receptor antagonist and a pituitary gonadotropin-releasing hormone analogue.
[0009] On the other hand, the present disclosure also provides a kit for treating or preventing breast cancer in patients who have undergone surgical treatment, comprising (a) a first pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as described in the present disclosure; and (b) a second pharmaceutical composition comprising an endocrine therapy drug.
[0010] On the other hand, the present disclosure provides a combination pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and an endocrine therapy drug, wherein the endocrine therapy drug is selected from an estrogen receptor antagonist, a pituitary gonadotropin-releasing hormone analogue, a combination of an aromatase inhibitor and a pituitary gonadotropin-releasing hormone analogue, or a combination of an estrogen receptor antagonist and a pituitary gonadotropin-releasing hormone analogue.
[0011] On the other hand, the present disclosure also provides a kit comprising (a) a first pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as described in the present disclosure; and (b) a second pharmaceutical composition comprising an endocrine therapy drug; wherein the endocrine therapy drug is selected from an estrogen receptor antagonist, a pituitary gonadotropin-releasing hormone analogue, a combination of an aromatase inhibitor and a pituitary gonadotropin-releasing hormone analogue, or a combination of an estrogen receptor antagonist and a pituitary gonadotropin-releasing hormone analogue.
[0012] In some embodiments of the present disclosure, the aromatase inhibitor is selected from letrozole or anastrozole.
[0013] In some embodiments of the present disclosure, the estrogen receptor antagonist is selected from tamoxifen.
[0014] In some embodiments of the present disclosure, the pituitary gonadotropin-releasing hormone analog is selected from goserelin.
[0015] In some embodiments of the present disclosure, the endocrine therapy drug is selected from one or more of letrozole, anastrozole, tamoxifen, or goserelin, for example, one or two.
[0016] In some embodiments of the present disclosure, the endocrine therapy drug is selected from letrozole, anastrozole, tamoxifen, a combination of letrozole and goserelin, a combination of anastrozole and goserelin, or a combination of tamoxifen and goserelin.
[0017] In some embodiments of the present disclosure, the endocrine therapy drug is selected from tamoxifen, a combination of letrozole and goserelin, a combination of anastrozole and goserelin, or a combination of tamoxifen and goserelin.
[0018] In some embodiments of the present disclosure, the endocrine therapy drug is selected from letrozole, anastrozole, or tamoxifen.
[0019] In some embodiments of the present disclosure, the endocrine therapy drug is selected from tamoxifen.
[0020] In another aspect, the present disclosure provides a combination pharmaceutical composition for treating or preventing breast cancer in patients who have undergone surgical treatment, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and an aromatase inhibitor. Alternatively, the present disclosure provides a combination pharmaceutical composition for treating or preventing breast cancer in patients who have undergone surgical treatment, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a combination of an aromatase inhibitor and a pituitary gonadotropin-releasing hormone analogue.
[0021] In another aspect, the present disclosure provides a combination pharmaceutical composition for treating or preventing breast cancer, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and tamoxifen.
[0022] On the other hand, the present disclosure also provides a method for treating or preventing breast cancer in patients who have undergone surgical treatment, comprising administering to an individual in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and an endocrine drug, for example, administering to an individual in need thereof a therapeutically effective amount of the combination pharmaceutical composition described in the present disclosure.
[0023] On the other hand, the present disclosure also provides a combination therapy for treating an individual with breast cancer who has undergone surgical treatment, the method comprising administering to the individual a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of an endocrine drug.
[0024] On the other hand, the present disclosure also provides a combination therapy for treating an individual with breast cancer, the method comprising administering to the individual a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of an endocrine drug, wherein the endocrine therapy drug is selected from an estrogen receptor antagonist, a pituitary gonadotropin-releasing hormone analogue, a combination of an aromatase inhibitor and a pituitary gonadotropin-releasing hormone analogue, or a combination of an estrogen receptor antagonist and a pituitary gonadotropin-releasing hormone analogue.
[0025] On the other hand, the present disclosure also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with an endocrine drug in the preparation of a medicament for treating or preventing breast cancer in patients who have undergone surgical treatment, such as the use of the combined pharmaceutical composition described in the present disclosure in the preparation of a medicament for treating or preventing breast cancer in patients who have undergone surgical treatment. In some embodiments of the present disclosure, the combined pharmaceutical composition is the combined pharmaceutical composition described in the present disclosure.
[0026] On the other hand, the present disclosure also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with an endocrine drug for treating or preventing breast cancer in patients who have undergone surgical treatment, for example, the use of the combination pharmaceutical composition described in the present disclosure for treating or preventing breast cancer in patients who have undergone surgical treatment.
[0027] In some embodiments of the present disclosure, the compound of formula (I) or a pharmaceutically acceptable salt thereof and the endocrine therapy drug in the combination pharmaceutical composition are packaged in the same kit, and the kit further comprises instructions for using the compound of formula (I) or a pharmaceutically acceptable salt thereof and the endocrine therapy drug in combination to treat or prevent breast cancer in patients who have undergone surgical treatment.
[0028] In some embodiments of the present disclosure, the compound of formula (I) or a pharmaceutically acceptable salt thereof and the endocrine therapy drug in the combination pharmaceutical composition are separately packaged in respective kits, and the kit further comprises instructions for using the compound of formula (I) or a pharmaceutically acceptable salt thereof and the endocrine therapy drug in combination to treat or prevent breast cancer in patients who have undergone surgical treatment.
[0029] In some embodiments of the present disclosure, the compound of formula (I) or a pharmaceutically acceptable salt thereof and the endocrine therapeutic drug in the combination pharmaceutical composition are each in the form of a pharmaceutical composition and can be administered simultaneously, sequentially or intermittently.
[0030] In some embodiments of the present disclosure, the combination pharmaceutical composition includes a pharmaceutical composition of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition of an endocrine therapy drug.
[0031] In some embodiments of the present disclosure, the pharmaceutical composition of the compound of formula (I) or a pharmaceutically acceptable salt thereof and the pharmaceutical composition of the endocrine therapy drug in the combination pharmaceutical composition are packaged in the same kit, and the kit further contains instructions for using the pharmaceutical composition of the compound of formula (I) or a pharmaceutically acceptable salt thereof and the pharmaceutical composition of the endocrine therapy drug in combination to treat or prevent breast cancer in patients who have undergone surgical treatment.
[0032] In some embodiments of the present disclosure, the pharmaceutical composition of the compound of formula (I) or a pharmaceutically acceptable salt thereof and the pharmaceutical composition of the endocrine therapy drug in the combination pharmaceutical composition are separately packaged in respective kits, and the kit further comprises instructions for using the pharmaceutical composition of the compound of formula (I) or a pharmaceutically acceptable salt thereof and the pharmaceutical composition of the endocrine therapy drug in combination to treat or prevent breast cancer in patients who have undergone surgical treatment.
[0033] In some embodiments of the present disclosure, in the combination pharmaceutical composition, the pharmaceutically acceptable salt of the compound of formula (I) is a maleate salt, such as a monomaleate salt of the compound of formula (I).
[0034] In some embodiments of the present disclosure, the aromatase inhibitor is selected from letrozole or anastrozole.
[0035] In some embodiments of the present disclosure, the combination pharmaceutical composition contains 20-240 mg, 40-180 mg, 60-180 mg, 80-180 mg, 100-180 mg, 120-180 mg, or 150-180 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, calculated as a compound of formula (I). Alternatively, the combination pharmaceutical composition is in the form of a single-dose formulation, and the combination pharmaceutical composition contains 20-240 mg, 40-180 mg, 60-180 mg, 80-180 mg, 100-180 mg, 120-180 mg, or 150-180 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, calculated as a compound of formula (I).
[0036] In some embodiments of the present disclosure, the combination pharmaceutical composition contains 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 150 mg, 180 mg or 240 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, calculated as a compound of formula (I).
[0037] In some embodiments of the present disclosure, the combination pharmaceutical composition contains 120 mg, 150 mg, or 180 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, calculated as a compound of formula (I). Alternatively, the combination pharmaceutical composition is in the form of a single-dose formulation, containing 120 mg, 150 mg, or 180 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, calculated as a compound of formula (I).
[0038] In some embodiments of the present disclosure, in the combination pharmaceutical composition, the pharmaceutical composition of the compound of formula (I) or a pharmaceutically acceptable salt thereof is in a single-dose or multi-dose form; in some embodiments of the present disclosure, in the combination pharmaceutical composition, the pharmaceutical composition of the compound of formula (I) or a pharmaceutically acceptable salt thereof is in a multi-dose form.
[0039] In some embodiments of the present disclosure, in the combination pharmaceutical composition, the content of the compound of formula (I) or a pharmaceutically acceptable salt thereof is a daily dose or a one-day dose.
[0040] In some embodiments of the present disclosure, the content of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the combination pharmaceutical composition is a once-daily dose or a once-daily dose.
[0041] In some embodiments of the present disclosure, in the combination pharmaceutical composition, the content of the compound of formula (I) or a pharmaceutically acceptable salt thereof is a once-daily dose or a once-daily dose, and each dose is a single dose or multiple doses, preferably multiple doses.
[0042] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a single dose of 50 mg, 60 mg, 120 mg, 150 mg or 180 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof.
[0043] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a single dose of 50 mg or 60 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof, calculated as the compound of formula (I).
[0044] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a single dose of 60 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof, calculated as the compound of formula (I).
[0045] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a compound of formula (I) or a pharmaceutically acceptable salt thereof and an endocrine therapy drug in a mass ratio of 1:1 to 200:1, preferably 10:1 to 200:1, 6:1 to 180:1, 6:1 to 90:1, 6:1 to 9:1, 48:1 to 72:1, 120:1 to 180:1, or any ratio within the above ranges, wherein the amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof is based on the mass of the compound of formula (I), and the amount of the endocrine therapy drug is based on the mass of the active ingredient therein.
[0046] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a compound of formula (I) or a pharmaceutically acceptable salt thereof and an aromatase inhibitor in a mass ratio of 1:1 to 200:1, preferably 10:1 to 200:1, 20:1 to 200:1, 40:1 to 180:1, 48:1 to 72:1, 120:1 to 180:1, or any ratio within the above ranges, wherein the amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof is based on the mass of the compound of formula (I), and the amount of the aromatase inhibitor is based on the mass of the active ingredient therein.
[0047] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a compound of formula (I) or a pharmaceutically acceptable salt thereof and an estrogen receptor antagonist in a mass ratio of 1:1 to 200:1, preferably 1.5:1 to 180:1, 6:1 to 180:1, 6:1 to 90:1, or any ratio within the above ranges, wherein the amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof is based on the mass of the compound of formula (I), and the amount of the estrogen receptor antagonist is based on the mass of the active ingredient therein.
[0048] In some embodiments of the present disclosure, the pharmaceutical composition of the compound of formula (I) or a pharmaceutically acceptable salt thereof contained in the combination pharmaceutical composition is packaged in a kit, which also contains instructions for using the compound of formula (I) or a pharmaceutically acceptable salt thereof to treat or prevent breast cancer in patients who have undergone surgical treatment.
[0049] Pharmaceutical composition of a compound of formula (I) or a pharmaceutically acceptable salt thereof and letrozole
[0050] In some embodiments of the present disclosure, the present disclosure provides a combination pharmaceutical composition for treating or preventing breast cancer in patients who have undergone surgical treatment, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and letrozole.
[0051] In some embodiments of the present disclosure, the combination pharmaceutical composition contains 2.5 mg to 12.5 mg, 2.5 mg to 10 mg, 2.5 mg to 7.5 mg, or 2.5 mg to 5 mg of letrozole, or a pharmaceutical composition thereof. Alternatively, the combination pharmaceutical composition is in the form of a single-dose formulation, and the combination pharmaceutical composition contains 2.5 mg to 12.5 mg, 2.5 mg to 10 mg, 2.5 mg to 7.5 mg, or 2.5 mg to 5 mg of letrozole, or a pharmaceutical composition thereof.
[0052] In some embodiments of the present disclosure, the combination pharmaceutical composition contains 2.5 mg, 5 mg, 7.5 mg or 10 mg of letrozole, or a pharmaceutical composition thereof. In some embodiments of the present disclosure, the combination pharmaceutical composition contains 2.5 mg of letrozole, or a pharmaceutical composition thereof.
[0053] In some embodiments of the present disclosure, in the combination pharmaceutical composition, the pharmaceutical composition of letrozole is in the form of a single dose or multiple doses. In some embodiments of the present disclosure, in the combination pharmaceutical composition, the pharmaceutical composition of letrozole is in the form of a single dose. In some embodiments of the present disclosure, in the combination pharmaceutical composition, the content of letrozole is a daily dose or a daily dose. In some embodiments of the present disclosure, in the combination pharmaceutical composition, the content of letrozole is a once-daily dose or a once-daily dose. In some embodiments of the present disclosure, in the combination pharmaceutical composition, the content of letrozole is a once-daily dose or a once-daily dose, and each dose is a single dose or multiple doses, preferably a single dose.
[0054] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a single dose of 2.5 mg of letrozole.
[0055] In some embodiments of the present disclosure, the pharmaceutical composition of letrozole contained in the combination pharmaceutical composition is packaged in a kit, and the kit also contains instructions for using letrozole to treat or prevent breast cancer in patients who have received surgical treatment.
[0056] In some embodiments of the present disclosure, the pharmaceutical composition of letrozole contained in the combination pharmaceutical composition is packaged in a kit, which also contains instructions for using letrozole to treat or prevent breast cancer in patients who have undergone surgical treatment. The instructions can be the instructions in the instructions of a commercially available letrozole kit.
[0057] In some embodiments of the present disclosure, the combination pharmaceutical composition contains, calculated as the compound of formula (I), 20-240 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof and 2.5 mg-12.5 mg of letrozole.
[0058] In some embodiments of the present disclosure, the combination pharmaceutical composition contains, calculated as the compound of formula (I), 120-180 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof and 2.5 mg-5 mg of letrozole.
[0059] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a daily dose of 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 150 mg, 180 mg or 240 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof; and a daily dose of 2.5 mg of letrozole.
[0060] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a daily dose of 120 mg, 150 mg or 180 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and a daily dose of 2.5 mg of letrozole.
[0061] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a pharmaceutical composition comprising a single dose of 50 mg or 60 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof, calculated as a compound of formula (I); and a pharmaceutical composition comprising a single dose of 2.5 mg of letrozole.
[0062] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a pharmaceutical composition of a single dose of 60 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof, calculated as the compound of formula (I); and a pharmaceutical composition containing a single dose of 2.5 mg of letrozole.
[0063] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof and letrozole or a pharmaceutical composition thereof in a mass ratio of 1:1 to 200:1, preferably 10:1 to 200:1, 20:1 to 150:1, 24:1 to 144:1, 24:1 to 72:1, 48:1 to 72:1, or any ratio within the above ranges, wherein the amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is based on the mass of the compound of formula (I), and the amount of letrozole or its pharmaceutical composition is based on the mass of letrozole.
[0064] In some embodiments of the present disclosure, the combination pharmaceutical composition is a preparation suitable for administration in a single treatment cycle (e.g., 28 days), the preparation containing: a total amount of 1680mg-5040mg (e.g., 3360mg-5040mg, preferably 3360mg, 4200mg, 5040mg) of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof; and a total amount of 70mg-140mg (e.g., 70mg) of letrozole or a pharmaceutical composition thereof, wherein the amount of the compound of formula (I) or its pharmaceutically acceptable salt or its pharmaceutical composition is based on the mass of the compound of formula (I), and the amount of letrozole or its pharmaceutical composition is based on the mass of letrozole. In some preferred embodiments, the compound of formula (I) or its pharmaceutically acceptable salt or its pharmaceutical composition is packaged in a single aliquot or multiple aliquots (e.g., 2 aliquots, 4 aliquots, 7 aliquots, 14 aliquots, 28 aliquots or more). In some preferred embodiments, the letrozole or its pharmaceutical composition is packaged in a single aliquot or multiple aliquots (e.g., 2 aliquots, 4 aliquots, 7 aliquots, 14 aliquots, 28 aliquots, or more). In some embodiments, the compound of formula (I) or its pharmaceutically acceptable salt or its pharmaceutical composition and the letrozole or its pharmaceutical composition are packaged separately or together.
[0065] In some embodiments of the present disclosure, the combination pharmaceutical composition is a preparation suitable for administration in a single treatment cycle (e.g., 28 days), comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof and letrozole or a pharmaceutical composition thereof in a mass ratio of 12:1 to 72:1, e.g., 24:1 to 72:1, 48:1 to 72:1, 48:1, 60:1, 72:1, or any ratio within the above ranges, wherein the amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is based on the mass of the compound of formula (I), and the amount of letrozole or its pharmaceutical composition is based on the mass of letrozole.
[0066] In some embodiments of the present disclosure, in the combination pharmaceutical composition, the compound of formula (I) or a pharmaceutically acceptable salt thereof and letrozole can be in the form of a pharmaceutical composition separately or together.
[0067] On the other hand, the present disclosure also provides a kit for treating or preventing breast cancer in patients who have undergone surgical treatment, comprising (a) a first pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as described in the present disclosure; and (b) a second pharmaceutical composition comprising letrozole.
[0068] On the other hand, the present disclosure also provides a kit comprising a pharmaceutical composition for treating or preventing breast cancer in patients who have undergone surgical treatment, wherein the kit comprises (a) a first pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as described in the present disclosure; and (b) a second pharmaceutical composition comprising letrozole.
[0069] On the other hand, the present disclosure also provides a method for treating or preventing breast cancer in patients who have undergone surgical treatment, comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and letrozole to an individual in need thereof, for example, administering a therapeutically effective amount of the combination pharmaceutical composition described in the present disclosure to an individual in need thereof.
[0070] In another aspect, the present disclosure also provides a combination therapy for treating an individual with breast cancer who has undergone surgical treatment, the method comprising administering to the individual a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of letrozole.
[0071] On the other hand, the present disclosure also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with letrozole in the preparation of a medicament for treating or preventing breast cancer in patients who have undergone surgical treatment, such as the use of the combination pharmaceutical composition described in the present disclosure in the preparation of a medicament for treating or preventing breast cancer in patients who have undergone surgical treatment. In some embodiments of the present disclosure, the combination pharmaceutical composition is the combination pharmaceutical composition described in the present disclosure.
[0072] On the other hand, the present disclosure also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with letrozole for treating or preventing breast cancer in patients who have undergone surgical treatment, for example, the use of the above-mentioned combination pharmaceutical composition of the present disclosure for treating or preventing breast cancer in patients who have undergone surgical treatment.
[0073] In some embodiments of the present disclosure, in the kit, method, combination therapy or use, the definitions of the compound of formula (I) or a pharmaceutically acceptable salt thereof and letrozole are the same as the definitions of the compound of formula (I) or a pharmaceutically acceptable salt thereof and letrozole in the combination pharmaceutical composition described in the present disclosure, such as content, dosage, form of existence, packaging form, etc.
[0074] In some embodiments of the present disclosure, in the method, combination therapy or use, the compound of formula (I) or a pharmaceutically acceptable salt thereof and letrozole are each in the form of a pharmaceutical composition and can be administered simultaneously, separately, concurrently, sequentially or intermittently.
[0075] In some embodiments of the present disclosure, in the method, combination therapy or use, the compound of formula (I) or a pharmaceutically acceptable salt thereof and letrozole have the same or different treatment cycles, respectively. In some specific embodiments of the present disclosure, in the method, combination therapy or use, the compound of formula (I) or a pharmaceutically acceptable salt thereof and letrozole have the same treatment cycle, for example, every 1 week, every 2 weeks, every 3 weeks or every 4 weeks is a treatment cycle.
[0076] In some embodiments of the present disclosure, in the method, combination therapy or use, the content of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the combination pharmaceutical composition is a daily dose, which is administered as follows: the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered once a day.
[0077] In some embodiments of the present disclosure, in the method, combination therapy or use, the content of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the combination pharmaceutical composition is a daily dose, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a single dose or multiple doses, usually in multiple doses; further, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered once a day.
[0078] In some embodiments of the present disclosure, in the method, combination therapy or use, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered as follows: a daily dose of 120 mg; or, a daily dose of 150 mg; or, a daily dose of 180 mg.
[0079] In some embodiments of the present disclosure, in the methods, combination therapies, or uses, the compound of formula (I) or a pharmaceutically acceptable salt thereof in the combination pharmaceutical composition is administered in multiple doses, wherein the multiple doses consist of a single dose of 50 mg or 60 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof; preferably, the multiple doses consist of a single dose of 60 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments of the present disclosure, in the methods, combination therapies, or uses, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a continuous daily dosing manner.
[0080] In some embodiments of the present disclosure, in the method, combination therapy or use, the content of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the combination pharmaceutical composition is a dose per treatment cycle, which is administered as follows: administering the compound of formula (I) or a pharmaceutically acceptable salt thereof every day.
[0081] In some embodiments of the present disclosure, in the method, combination therapy or use, the content of letrozole in the combination pharmaceutical composition is a daily dose, which is administered in the following manner: letrozole is administered once a day.
[0082] In some embodiments of the present disclosure, in the method, combination therapy or use, the content of letrozole in the combination pharmaceutical composition is a daily dose, wherein letrozole is administered in a single dose or multiple doses, usually in a single dose; further, wherein letrozole is administered once a day.
[0083] In some embodiments of the present disclosure, in the method, combination therapy, or use, the letrozole is administered in a daily dose of 2.5 mg.
[0084] In some embodiments of the present disclosure, in the methods, combination therapies, or uses, the letrozole in the combination pharmaceutical composition is administered as a single dose, wherein the single dose is 2.5 mg of the pharmaceutical composition. In some embodiments of the present disclosure, in the methods, combination therapies, or uses, the letrozole is administered as a continuous daily dose.
[0085] In some embodiments of the present disclosure, in the method, combination therapy or use, the content of letrozole in the combination pharmaceutical composition is a dose per treatment cycle, which is administered by administering letrozole every day.
[0086] In some embodiments of the present disclosure, in the method, combination therapy or use, 28 days is a treatment cycle, and the compound of formula (I) or a pharmaceutically acceptable salt thereof and letrozole are administered daily on days 1 to 28 of each treatment cycle.
[0087] In some specific embodiments of the present disclosure, in the method, combination therapy or use, 28 days is a treatment cycle, and the compound of formula (I) or a pharmaceutically acceptable salt thereof and letrozole are administered once a day on days 1 to 28 of each treatment cycle.
[0088] In some embodiments of the present disclosure, in the method, combination therapy or use, 28 days is a treatment cycle, the drug is administered once a day for 28 consecutive days, and the total dose of the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof for each treatment cycle is 3360-5040 mg. In some embodiments of the present disclosure, the total dose of the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from 3360 mg, 4200 mg, 5040 mg or the range formed by any two of the above values. In some embodiments of the present disclosure, the total dose of the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof is preferably 5040 mg.
[0089] In some embodiments of the present disclosure, in the methods, combination therapies, or uses, 28 days is a treatment cycle, the drug is administered once a day for 28 consecutive days, and the total dose of the pharmaceutical composition containing letrozole administered per treatment cycle is 70-210 mg. In some embodiments of the present disclosure, the total dose of the pharmaceutical composition containing letrozole is selected from 70 mg, 140 mg, 210 mg, or a range formed by any two of the above values. In some embodiments of the present disclosure, the total dose of the pharmaceutical composition containing letrozole is preferably 70 mg.
[0090] In some embodiments of the present disclosure, in the method, combination therapy or use, 28 days is a treatment cycle, the drug is administered once a day for 28 consecutive days, and a total dose of 5040 mg of a pharmaceutical composition containing a compound of formula (I) or a pharmaceutically acceptable salt thereof and a total dose of 70 mg of a pharmaceutical composition containing letrozole are administered in each treatment cycle.
[0091] In embodiments of the present disclosure, the above-described treatment cycles are repeated as long as the disease remains under control and the dosing regimen is clinically tolerated.
[0092] In some embodiments of the present disclosure, the letrozole is prepared as a single dose or multiple doses of 2.5 mg-7.5 mg or 2.5 mg-5 mg of letrozole suitable for continuous daily administration to the patient; the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof is prepared as a single dose or multiple doses of 120 mg, 150 mg and / or 180 mg of the compound of formula (I) itself suitable for continuous daily administration to the patient.
[0093] In some embodiments of the present disclosure, the letrozole is prepared as a single dose of 2.5 mg of letrozole suitable for continuous daily administration to the patient; the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof is prepared as multiple doses of 180 mg of the compound of formula (I) itself suitable for continuous daily administration to the patient.
[0094] Pharmaceutical composition of a compound of formula (I) or a pharmaceutically acceptable salt thereof and anastrozole
[0095] In some embodiments of the present disclosure, the present disclosure provides a combination pharmaceutical composition for treating or preventing breast cancer in patients who have received surgical treatment, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and anastrozole.
[0096] In some embodiments of the present disclosure, the combination pharmaceutical composition contains 1 mg-5 mg, 1 mg-4 mg, 1 mg-3 mg, or 1 mg-2 mg of anastrozole, or a pharmaceutical composition thereof. Alternatively, the combination pharmaceutical composition is in the form of a single-dose formulation, and the combination pharmaceutical composition contains 1 mg-5 mg, 1 mg-4 mg, 1 mg-3 mg, or 1 mg-2 mg of anastrozole, or a pharmaceutical composition thereof.
[0097] In some embodiments of the present disclosure, the combination pharmaceutical composition contains 1 mg, 2 mg, 3 mg or 4 mg of anastrozole, or a pharmaceutical composition thereof. In some embodiments of the present disclosure, the combination pharmaceutical composition contains 1 mg of anastrozole, or a pharmaceutical composition thereof.
[0098] In some embodiments of the present disclosure, in the combination pharmaceutical composition, the pharmaceutical composition of anastrozole is in the form of a single dose or multiple doses. In some embodiments of the present disclosure, in the combination pharmaceutical composition, the pharmaceutical composition of anastrozole is in the form of a single dose. In some embodiments of the present disclosure, in the combination pharmaceutical composition, the content of anastrozole is a daily dose or a daily dose. In some embodiments of the present disclosure, in the combination pharmaceutical composition, the content of anastrozole is a once-daily dose or a once-a-day dose. In some embodiments of the present disclosure, in the combination pharmaceutical composition, the content of anastrozole is a once-daily dose or a once-a-day dose, and each dose is a single dose or multiple doses, preferably a single dose.
[0099] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a single dose of 1 mg of anastrozole.
[0100] In some embodiments of the present disclosure, the combination pharmaceutical composition contains anastrozole in a kit, which also contains instructions for using anastrozole to treat or prevent breast cancer in patients who have undergone surgical treatment.
[0101] In some embodiments of the present disclosure, the pharmaceutical composition of anastrozole contained in the combination pharmaceutical composition is packaged in a kit, and the kit also contains instructions for using anastrozole to treat or prevent breast cancer in patients who have undergone surgical treatment. The instructions can be the instructions in the instructions of a commercially available anastrozole kit.
[0102] In some embodiments of the present disclosure, the combination pharmaceutical composition contains 20-240 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof and 1 mg-5 mg of anastrozole.
[0103] In some embodiments of the present disclosure, the combination pharmaceutical composition contains, calculated as the compound of formula (I), 120-180 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof and 1 mg-2 mg of anastrozole.
[0104] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a daily dose of 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 150 mg, 180 mg or 240 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof; and a daily dose of 1 mg of anastrozole.
[0105] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a daily dose of 120 mg, 150 mg or 180 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and a daily dose of 1 mg of anastrozole.
[0106] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a pharmaceutical composition comprising a single dose of 50 mg or 60 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof, calculated as a compound of formula (I); and a pharmaceutical composition comprising a single dose of 1 mg of anastrozole.
[0107] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a pharmaceutical composition comprising a single dose of 60 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof, calculated as a compound of formula (I); and a pharmaceutical composition comprising a single dose of 1 mg of anastrozole.
[0108] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof and anastrozole or a pharmaceutical composition thereof in a mass ratio of 5:1 to 200:1, preferably 6:1 to 180:1, 10:1 to 180:1, 50:1 to 180:1, 60:1 to 180:1, 120:1 to 180:1, 150:1 to 180:1, or any ratio within the above ranges, wherein the amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is based on the mass of the compound of formula (I), and the amount of anastrozole or a pharmaceutical composition thereof is based on the mass of anastrozole.
[0109] In some embodiments of the present disclosure, the combination pharmaceutical composition is a preparation suitable for administration in a single treatment cycle (e.g., 28 days), comprising: a total amount of 1680 mg-5040 mg (e.g., 3360 mg-5040 mg, preferably 3360 mg, 4200 mg, 5040 mg) of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof; and a total amount of 28 mg-140 mg (e.g., 28 mg-56 mg, preferably 28 mg) of anastrozole or a pharmaceutical composition thereof, wherein the amount of the compound of formula (I) or its pharmaceutically acceptable salt or its pharmaceutical composition is based on the mass of the compound of formula (I), and the anastrozole or its pharmaceutical composition is based on the mass of anastrozole. In some preferred embodiments, the compound of formula (I) or its pharmaceutically acceptable salt or its pharmaceutical composition is packaged in a single aliquot or multiple aliquots (e.g., 2 aliquots, 4 aliquots, 7 aliquots, 14 aliquots, 28 aliquots, or more). In some preferred embodiments, the anastrozole or pharmaceutical composition thereof is packaged in a single aliquot or multiple aliquots (e.g., 2 aliquots, 4 aliquots, 7 aliquots, 14 aliquots, 28 aliquots, or more). In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof and the anastrozole or pharmaceutical composition thereof are packaged separately or together.
[0110] In some embodiments of the present disclosure, the combination pharmaceutical composition is a preparation suitable for administration in a single treatment cycle (e.g., 28 days), comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, and anastrozole or a pharmaceutical composition thereof in a mass ratio of 12:1 to 180:1, e.g., 24:1 to 180:1, 30:1 to 180:1, 60:1 to 180:1, 120:1 to 180:1, 150:1 to 180:1, 180:1, or any ratio within the above ranges, wherein the amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is based on the mass of the compound of formula (I), and the anastrozole or a pharmaceutical composition thereof is based on the mass of the anastrozole.
[0111] In some embodiments of the present disclosure, in the combination pharmaceutical composition, the compound of formula (I) or a pharmaceutically acceptable salt thereof and anastrozole can be in the form of a pharmaceutical composition separately or together.
[0112] On the other hand, the present disclosure also provides a kit for treating or preventing breast cancer in patients who have undergone surgical treatment, comprising (a) a first pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as described in the present disclosure; and (b) a second pharmaceutical composition comprising anastrozole.
[0113] On the other hand, the present disclosure also provides a kit comprising a pharmaceutical composition for treating or preventing breast cancer in patients who have undergone surgical treatment, wherein the kit comprises (a) a first pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as described in the present disclosure; and (b) a second pharmaceutical composition comprising anastrozole.
[0114] On the other hand, the present disclosure also provides a method for treating or preventing breast cancer in patients who have undergone surgical treatment, comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and anastrozole to an individual in need thereof, for example, administering a therapeutically effective amount of the combination pharmaceutical composition described in the present disclosure to an individual in need thereof.
[0115] In another aspect, the present disclosure also provides a combination therapy for treating an individual with breast cancer who has undergone surgical treatment, the method comprising administering to the individual a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of anastrozole.
[0116] On the other hand, the present disclosure also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with anastrozole in the preparation of a medicament for treating or preventing breast cancer in patients who have undergone surgical treatment, such as the use of the combination pharmaceutical composition described in the present disclosure in the preparation of a medicament for treating or preventing breast cancer in patients who have undergone surgical treatment. In some embodiments of the present disclosure, the combination pharmaceutical composition is the combination pharmaceutical composition described in the present disclosure.
[0117] On the other hand, the present disclosure also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with anastrozole for treating or preventing breast cancer in patients who have undergone surgical treatment, for example, the use of the combination pharmaceutical composition described in the present disclosure for treating or preventing breast cancer in patients who have undergone surgical treatment.
[0118] In some embodiments of the present disclosure, in the kit, method, combination therapy or use, the definitions of the compound of formula (I) or its pharmaceutically acceptable salt and anastrozole are the same as the definitions of the compound of formula (I) or its pharmaceutically acceptable salt and anastrozole in the combination pharmaceutical composition described in the present disclosure, such as content, dosage, form of existence, packaging form, etc.
[0119] In some embodiments of the present disclosure, in the method, combination therapy or use, the compound of formula (I) or a pharmaceutically acceptable salt thereof and anastrozole are each in the form of a pharmaceutical composition and can be administered simultaneously, separately, concurrently, sequentially or intermittently.
[0120] In some embodiments of the present disclosure, in the methods, combination therapies, or uses, the compound of formula (I) or a pharmaceutically acceptable salt thereof and anastrozole have the same or different treatment cycles, respectively. In some specific embodiments of the present disclosure, in the methods, combination therapies, or uses, the compound of formula (I) or a pharmaceutically acceptable salt thereof and anastrozole have the same treatment cycle, for example, one treatment cycle is one week, two weeks, three weeks, or four weeks.
[0121] In some embodiments of the present disclosure, in the method, combination therapy or use, the content of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the combination pharmaceutical composition is a daily dose, which is administered as follows: the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered once a day.
[0122] In some embodiments of the present disclosure, in the method, combination therapy or use, the content of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the combination pharmaceutical composition is a daily dose, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a single dose or multiple doses, usually in multiple doses; further, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered once a day.
[0123] In some embodiments of the present disclosure, in the method, combination therapy or use, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered as follows: a daily dose of 120 mg; or, a daily dose of 150 mg; or a daily dose of 180 mg.
[0124] In some embodiments of the present disclosure, in the methods, combination therapies, or uses, the compound of formula (I) or a pharmaceutically acceptable salt thereof in the combination pharmaceutical composition is administered in multiple doses, wherein the multiple doses consist of a single dose of 50 mg or 60 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof; preferably, the multiple doses consist of a single dose of 60 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments of the present disclosure, in the methods, combination therapies, or uses, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a continuous daily dosing manner.
[0125] In some embodiments of the present disclosure, in the method, combination therapy or use, the content of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the combination pharmaceutical composition is a dose per treatment cycle, which is administered as follows: administering the compound of formula (I) or a pharmaceutically acceptable salt thereof every day.
[0126] In some embodiments of the present disclosure, in the method, combination therapy or use, the content of anastrozole in the combination pharmaceutical composition is a daily dose, which is administered in the following manner: anastrozole is administered once a day.
[0127] In some embodiments of the present disclosure, in the method, combination therapy or use, the content of anastrozole in the combination pharmaceutical composition is a daily dose, wherein anastrozole is administered in a single dose or multiple doses, usually in a single dose; further, wherein anastrozole is administered once a day.
[0128] In some embodiments of the present disclosure, in the method, combination therapy, or use, the anastrozole is administered in a daily dose of 1 mg.
[0129] In some embodiments of the present disclosure, in the methods, combination therapies, or uses, the anastrozole in the combination pharmaceutical composition is administered as a single dose, wherein the single dose is 1 mg of the pharmaceutical composition of anastrozole. In some embodiments of the present disclosure, in the methods, combination therapies, or uses, the anastrozole is administered as a continuous daily dose.
[0130] In some embodiments of the present disclosure, in the method, combination therapy or use, the content of anastrozole in the combination pharmaceutical composition is a dose per treatment cycle, which is administered in the following manner: anastrozole is administered every day.
[0131] In some embodiments of the present disclosure, in the method, combination therapy or use, 28 days is a treatment cycle, and the compound of formula (I) or a pharmaceutically acceptable salt thereof and anastrozole are administered every day on days 1 to 28 of each treatment cycle.
[0132] In some specific embodiments of the present disclosure, in the method, combination therapy or use, 28 days is a treatment cycle, and the compound of formula (I) or a pharmaceutically acceptable salt thereof and anastrozole are administered once a day on days 1 to 28 of each treatment cycle.
[0133] In some embodiments of the present disclosure, in the method, combination therapy or use, 28 days is a treatment cycle, the drug is administered once a day for 28 consecutive days, and the total dose of the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof in each treatment cycle is 3360 to 5040 mg. In some embodiments, the total dose of the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from 3360 mg, 4200 mg, 5040 mg or the range formed by any two of the above values. In some embodiments, the total dose of the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof is preferably 5040 mg.
[0134] In some embodiments of the present disclosure, in the methods, combination therapies, or uses, 28 days is a treatment cycle, the drug is administered once a day for 28 consecutive days, and the total dose of the pharmaceutical composition containing anastrozole administered in each treatment cycle is 28-140 mg. In some embodiments of the present disclosure, the total dose of the pharmaceutical composition containing anastrozole is selected from 28 mg, 56 mg, 84 mg, or a range formed by any two of the above values. In some embodiments of the present disclosure, the total dose of the pharmaceutical composition containing anastrozole is preferably 28 mg.
[0135] In some embodiments of the present disclosure, in the method, combination therapy or use, 28 days is a treatment cycle, the drug is administered once a day for 28 consecutive days, and a total dose of 5040 mg of a pharmaceutical composition containing a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a total dose of 28 mg of a pharmaceutical composition containing anastrozole is administered in each treatment cycle.
[0136] In embodiments of the present disclosure, the above-described treatment cycles are repeated as long as the disease remains under control and the dosing regimen is clinically tolerated.
[0137] In some embodiments of the present disclosure, the anastrozole is prepared as a single dose or multiple doses of 1 mg-3 mg or 1 mg-2 mg of anastrozole suitable for continuous daily administration to the patient; the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof is prepared as a single dose or multiple doses of 120 mg, 150 mg and / or 180 mg of the compound of formula (I) itself suitable for continuous daily administration to the patient.
[0138] In some embodiments of the present disclosure, the anastrozole is prepared as a single dose of 1 mg of anastrozole suitable for continuous daily administration to the patient; the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof is prepared as multiple doses of 180 mg of the compound of formula (I) itself suitable for continuous daily administration to the patient.
[0139] Pharmaceutical composition of a compound of formula (I) or a pharmaceutically acceptable salt thereof and tamoxifen
[0140] In some embodiments of the present disclosure, the present disclosure provides a combination pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and tamoxifen. In some embodiments of the present disclosure, the present disclosure provides a combination pharmaceutical composition for treating or preventing breast cancer, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and tamoxifen.
[0141] In some embodiments of the present disclosure, the present disclosure provides a combination pharmaceutical composition for treating or preventing breast cancer in patients who have received surgical treatment, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and tamoxifen.
[0142] In some embodiments of the present disclosure, the combination pharmaceutical composition contains 10-40mg or 20mg-40mg of tamoxifen, or a pharmaceutical composition thereof. Alternatively, the combination pharmaceutical composition is in the form of a single-dose formulation, and the combination pharmaceutical composition contains 10-40mg or 20mg-40mg of tamoxifen, or a pharmaceutical composition thereof. In some embodiments of the present disclosure, the combination pharmaceutical composition contains 20mg or 40mg of tamoxifen, or a pharmaceutical composition thereof. In some embodiments of the present disclosure, the combination pharmaceutical composition contains 20mg of tamoxifen, or a pharmaceutical composition thereof.
[0143] In some embodiments of the present disclosure, in the combination pharmaceutical composition, the pharmaceutical composition of tamoxifen is in a single dose or multiple dose form. In some embodiments of the present disclosure, in the combination pharmaceutical composition, the pharmaceutical composition of tamoxifen is in a single dose form. In some embodiments of the present disclosure, in the combination pharmaceutical composition, the content of tamoxifen is a daily dose or a daily dose. In some embodiments of the present disclosure, in the combination pharmaceutical composition, the content of tamoxifen is a twice-daily dose or a twice-daily dose.
[0144] In some embodiments of the present disclosure, the content of tamoxifen in the combination pharmaceutical composition is twice a day or twice a day, and each dose is a single dose or multiple doses, preferably a single dose.
[0145] In some embodiments of the present disclosure, the combination pharmaceutical composition comprises a single dose of 10 mg of tamoxifen. Alternatively, the combination pharmaceutical composition comprises a single dose of 20 mg of tamoxifen.
[0146] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a pharmaceutical composition of tamoxifen packaged in a kit, and the kit also contains instructions for using tamoxifen to treat or prevent breast cancer.
[0147] In some embodiments of the present disclosure, the tamoxifen pharmaceutical composition contained in the combination pharmaceutical composition is packaged in a kit, and the kit also contains instructions for using tamoxifen to treat or prevent breast cancer, which can be the instructions in the instructions of a commercially available tamoxifen kit.
[0148] In some embodiments of the present disclosure, the combination pharmaceutical composition contains 20-240 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof and 20 mg-40 mg of tamoxifen, calculated as the compound of formula (I).
[0149] In some embodiments of the present disclosure, the combination pharmaceutical composition contains 120-180 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof and 20 mg or 40 mg of tamoxifen.
[0150] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a daily dose of 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 150 mg, 180 mg or 240 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof; and a daily dose of 20 mg of tamoxifen.
[0151] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a daily dose of 120 mg, 150 mg or 180 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and a daily dose of 20 mg of tamoxifen.
[0152] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a pharmaceutical composition comprising a single dose of 50 mg or 60 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof, calculated as a compound of formula (I); and a pharmaceutical composition comprising a single dose of 10 mg of tamoxifen.
[0153] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a pharmaceutical composition comprising a single dose of 60 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof, calculated as a compound of formula (I); and a pharmaceutical composition comprising a single dose of 10 mg of tamoxifen.
[0154] In some embodiments of the present disclosure, the combination pharmaceutical composition contains a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof and tamoxifen or a pharmaceutical composition thereof in a mass ratio of 1:1 to 200:1, preferably 1:1 to 180:1, 6:1 to 180:1, 6:1 to 150:1, 6:1 to 100:1, 6:1 to 90:1, 6:1 to 10:1, 6:1 to 9:1, or any ratio within the above ranges, wherein the amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is based on the mass of the compound of formula (I), and the amount of tamoxifen or a pharmaceutical composition thereof is based on the mass of tamoxifen.
[0155] In some embodiments of the present disclosure, the combination pharmaceutical composition is a preparation suitable for administration in a single treatment cycle (e.g., 28 days), the preparation containing: a total amount of 1680mg-5040mg (e.g., 3360mg-5040mg, preferably 3360mg, 4200mg, 5040mg) of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof; and a total amount of 560mg-1120mg (e.g., 560mg) of tamoxifen or a pharmaceutical composition thereof, wherein the amount of the compound of formula (I) or its pharmaceutically acceptable salt or its pharmaceutical composition is based on the mass of the compound of formula (I), and the tamoxifen or its pharmaceutical composition is based on the mass of tamoxifen. In some preferred embodiments, the compound of formula (I) or its pharmaceutically acceptable salt or its pharmaceutical composition is packaged in a single aliquot or multiple aliquots (e.g., 2 aliquots, 4 aliquots, 7 aliquots, 14 aliquots, 28 aliquots or more). In some preferred embodiments, the tamoxifen or its pharmaceutical composition is packaged in a single aliquot or multiple aliquots (e.g., 2 aliquots, 4 aliquots, 7 aliquots, 14 aliquots, 28 aliquots, or more). In some embodiments, the compound of formula (I) or its pharmaceutically acceptable salt or its pharmaceutical composition and the tamoxifen or its pharmaceutical composition are packaged separately or together.
[0156] In some embodiments of the present disclosure, the combination pharmaceutical composition is a preparation suitable for administration in a single treatment cycle (e.g., 28 days), comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, and tamoxifen or a pharmaceutical composition thereof in a mass ratio of 1.5:1 to 180:1, e.g., 6:1 to 180:1, 6:1 to 120:1, 6:1 to 90:1, 6:1 to 60:1, 6:1 to 30:1, 6:1 to 9:1, 7.5:1, or any ratio within the above ranges, wherein the amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is based on the mass of the compound of formula (I), and the tamoxifen or a pharmaceutical composition thereof is based on the mass of tamoxifen.
[0157] In some embodiments of the present disclosure, in the combination pharmaceutical composition, the compound of formula (I) or a pharmaceutically acceptable salt thereof and tamoxifen can be in the form of a pharmaceutical composition separately or together.
[0158] In another aspect, the present disclosure further provides a kit comprising (a) a first pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as described herein; and (b) a second pharmaceutical composition comprising tamoxifen.
[0159] On the other hand, the present disclosure also provides a kit comprising a pharmaceutical composition for treating or preventing breast cancer, which contains (a) a first pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof as described in the present disclosure; and (b) a second pharmaceutical composition containing tamoxifen.
[0160] On the other hand, the present disclosure also provides a method for treating or preventing breast cancer, comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and tamoxifen to an individual in need thereof, for example, administering a therapeutically effective amount of the combination pharmaceutical composition described above of the present disclosure to an individual in need thereof.
[0161] In another aspect, the present disclosure also provides a combination therapy for treating an individual suffering from breast cancer, comprising administering to the individual a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of tamoxifen.
[0162] On the other hand, the present disclosure also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with tamoxifen in the preparation of a medicament for treating or preventing breast cancer, for example, the use of the above-mentioned combination pharmaceutical composition of the present disclosure in the preparation of a medicament for treating or preventing breast cancer. In some embodiments of the present disclosure, the combination pharmaceutical composition is the combination pharmaceutical composition described in the present disclosure.
[0163] On the other hand, the present disclosure also provides the use of the compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with tamoxifen for treating or preventing breast cancer, for example, the use of the above-mentioned combination pharmaceutical composition of the present disclosure for treating or preventing breast cancer.
[0164] In some embodiments of the present disclosure, in the kit, method, combination therapy or use, the definitions of the compound of formula (I) or a pharmaceutically acceptable salt thereof and tamoxifen are the same as the definitions of the compound of formula (I) or a pharmaceutically acceptable salt thereof and tamoxifen in the combination pharmaceutical composition described in the present disclosure, such as content, dosage, form of existence, packaging form, etc.
[0165] In some embodiments of the present disclosure, in the method, combination therapy or use, the compound of formula (I) or a pharmaceutically acceptable salt thereof and tamoxifen are each in the form of a pharmaceutical composition and can be administered simultaneously, separately, concurrently, sequentially or intermittently.
[0166] In some embodiments of the present disclosure, in the method, combination therapy or use, the compound of formula (I) or a pharmaceutically acceptable salt thereof and tamoxifen have the same or different treatment cycles, respectively. In some specific embodiments of the present disclosure, in the method, combination therapy or use, the compound of formula (I) or a pharmaceutically acceptable salt thereof and tamoxifen have the same treatment cycle, for example, every 1 week, every 2 weeks, every 3 weeks or every 4 weeks is a treatment cycle.
[0167] In some embodiments of the present disclosure, in the method, combination therapy or use, the content of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the combination pharmaceutical composition is a daily dose, which is administered as follows: the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered once a day.
[0168] In some embodiments of the present disclosure, in the method, combination therapy or use, the content of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the combination pharmaceutical composition is a daily dose, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a single dose or multiple doses, usually in multiple doses; further, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered once a day.
[0169] In some embodiments of the present disclosure, in the method, combination therapy or use, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered as follows: a daily dose of 120 mg; or, a daily dose of 150 mg; or a daily dose of 180 mg.
[0170] In some embodiments of the present disclosure, in the methods, combination therapies, or uses, the compound of formula (I) or a pharmaceutically acceptable salt thereof in the combination pharmaceutical composition is administered in multiple doses, wherein the multiple doses consist of a single dose of 50 mg or 60 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof; preferably, the multiple doses consist of a single dose of 60 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments of the present disclosure, in the methods, combination therapies, or uses, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a continuous daily dosing manner.
[0171] In some embodiments of the present disclosure, in the method, combination therapy or use, the content of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the combination pharmaceutical composition is a dose per treatment cycle, which is administered as follows: administering the compound of formula (I) or a pharmaceutically acceptable salt thereof every day.
[0172] In some embodiments of the present disclosure, in the method, combination therapy or use, the amount of tamoxifen in the combination pharmaceutical composition is a daily dose, which is administered as follows: tamoxifen is administered twice a day.
[0173] In some embodiments of the present disclosure, in the methods, combination therapies or uses, the amount of tamoxifen in the combination pharmaceutical composition is a daily dose, wherein tamoxifen is administered in a single dose or multiple doses, typically in a single dose; further, wherein tamoxifen is administered twice daily.
[0174] In some embodiments of the present disclosure, in the method, combination therapy, or use, the tamoxifen is administered in a daily dose of 20 mg.
[0175] In some embodiments of the present disclosure, in the methods, combination therapies, or uses, the tamoxifen in the combination pharmaceutical composition is administered as a single dose, wherein the single dose is a pharmaceutical composition of 10 mg of tamoxifen. In some embodiments of the present disclosure, in the methods, combination therapies, or uses, the tamoxifen is administered as a continuous daily dose.
[0176] In some embodiments of the present disclosure, in the method, combination therapy or use, the content of tamoxifen in the combination pharmaceutical composition is a dose per treatment cycle, which is administered in the following manner: administer tamoxifen every day.
[0177] In some embodiments of the present disclosure, in the method, combination therapy or use, 28 days is a treatment cycle, and the compound of formula (I) or a pharmaceutically acceptable salt thereof and tamoxifen are administered daily on days 1 to 28 of each treatment cycle.
[0178] In some specific embodiments of the present disclosure, in the method, combination therapy or use, 28 days is a treatment cycle, and the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered once a day on days 1 to 28 of each treatment cycle, and tamoxifen is administered twice a day on days 1 to 28 of each treatment cycle.
[0179] In some embodiments of the present disclosure, in the method, combination therapy or use, 28 days is a treatment cycle, the drug is administered once a day for 28 consecutive days, and the total dose of the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof in each treatment cycle is 3360-5040 mg. In some embodiments, the total dose of the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from 3360 mg, 4200 mg, 5040 mg or the range formed by any two of the above values. In some embodiments, the total dose of the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof is preferably 5040 mg.
[0180] In some embodiments of the present disclosure, in the method, combination therapy or use, 28 days is a treatment cycle, the drug is administered twice a day for 28 consecutive days, and the total dose of the pharmaceutical composition containing tamoxifen administered per treatment cycle is 560-1120 mg. In some embodiments of the present disclosure, the total dose of the pharmaceutical composition containing tamoxifen is selected from 560 mg or 1120 mg or the range formed by any two of the above values. In some embodiments of the present disclosure, the total dose of the pharmaceutical composition containing tamoxifen is preferably 560 mg.
[0181] In some embodiments of the present disclosure, in the method, combination therapy or use, 28 days is a treatment cycle, the drug is administered once a day for 28 consecutive days, and a total dose of 5040 mg of a pharmaceutical composition containing a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a total dose of 560 mg of a pharmaceutical composition containing tamoxifen is administered in each treatment cycle.
[0182] In embodiments of the present disclosure, the above-described treatment cycles are repeated as long as the disease remains under control and the dosing regimen is clinically tolerated.
[0183] In some embodiments of the present disclosure, the tamoxifen is prepared as a single dose or multiple doses of 10 mg-40 mg or 20 mg-40 mg of tamoxifen suitable for continuous daily administration to the patient; the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof is prepared as a single dose or multiple doses of 120 mg, 150 mg and / or 180 mg of the compound of formula (I) itself suitable for continuous daily administration to the patient.
[0184] In some embodiments of the present disclosure, the tamoxifen is prepared as a single dose of 10 mg of tamoxifen suitable for continuous daily administration to the patient; the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof is prepared as multiple doses of 180 mg of the compound of formula (I) itself suitable for continuous daily administration to the patient.
[0185] In some embodiments of the present disclosure, the method, combination therapy, or use is an adjuvant treatment method, therapy, or use. In some embodiments of the present disclosure, the method, combination therapy, or use is an adjuvant treatment method, therapy, or use for breast cancer. In some embodiments of the present disclosure, the method, combination therapy, or use is a method, therapy, or use for providing adjuvant treatment for a patient with breast cancer.
[0186] In some embodiments of the present disclosure, the surgical treatment is selected from radical resection or breast-conserving surgery. In some embodiments of the present disclosure, the breast-conserving surgery is a breast-conserving surgery with no residual invasive cancer and no residual ductal carcinoma in situ or lobular carcinoma in situ at the resection margin. For example, pathological examination confirms that there is no residual invasive cancer and no residual ductal carcinoma in situ or lobular carcinoma in situ at the resection margin after breast-conserving surgery.
[0187] In some embodiments of the present disclosure, the surgical treatment is selected from radical resection, or breast-conserving surgery with no residual invasive cancer and residual ductal carcinoma in situ or lobular carcinoma in situ at the resection margin. In some embodiments of the present disclosure, the radical resection is selected from modified radical resection, classic radical resection or extended radical resection. In some embodiments of the present disclosure, the radical breast cancer surgery consists of two parts: breast treatment and axillary treatment. In some embodiments of the present disclosure, there is no recurrence or distant metastasis after the surgical treatment (for example, there is no evidence of recurrence or distant metastasis after the surgical treatment). In some embodiments of the present disclosure, the surgical treatment is radical resection of breast cancer, or pathological examination confirms that there is no residual invasive cancer and residual ductal carcinoma in situ or lobular carcinoma in situ at the resection margin after breast-conserving surgery; and there is no evidence of recurrence or distant metastasis after the surgical treatment. In some embodiments of the present disclosure, the surgical treatment is selected from breast-conserving surgery, total mastectomy or reconstruction after total resection. In some embodiments of the present disclosure, the surgical treatment is surgical treatment for breast treatment and / or axillary treatment.
[0188] In some embodiments of the present disclosure, the breast cancer is selected from invasive breast cancer. Preferably, the breast cancer is selected from HR-positive, HER2-negative invasive breast cancer.
[0189] In some embodiments of the present disclosure, the breast cancer is selected from early-stage breast cancer.
[0190] In some embodiments of the present disclosure, the breast cancer is selected from early invasive breast cancer.
[0191] In some embodiments of the present disclosure, the breast cancer is selected from breast cancers with a high risk of recurrence.
[0192] In some embodiments of the present disclosure, the breast cancer is selected from hormone receptor (HR)-positive breast cancer.
[0193] In some embodiments of the present disclosure, the breast cancer is selected from human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
[0194] In some embodiments of the present disclosure, the breast cancer is selected from HR-positive, HER2-negative breast cancer. In some embodiments of the present disclosure, the breast cancer is selected from HR-positive, HER2-negative locally advanced and / or metastatic breast cancer.
[0195] In some embodiments of the present disclosure, the breast cancer is selected from breast cancers with a ki-67 index ≥ 20%.
[0196] In some embodiments of the present disclosure, the breast cancer is selected from lymph node-positive breast cancer.
[0197] In some embodiments of the present disclosure, the breast cancer is selected from breast cancer with a high risk of recurrence in patients who have received surgical treatment.
[0198] In some embodiments of the present disclosure, the breast cancer is selected from early-stage breast cancer in patients who have received surgical treatment.
[0199] In some embodiments of the present disclosure, the breast cancer is selected from HR-positive, HER2-negative breast cancer in patients who have received surgical treatment.
[0200] In some embodiments of the present disclosure, the breast cancer is selected from breast cancer with a ki-67 index ≥ 20% in patients who have received surgical treatment.
[0201] In some embodiments of the present disclosure, the breast cancer is selected from lymph node-positive breast cancer in patients who have received surgical treatment.
[0202] In some embodiments of the present disclosure, the breast cancer is selected from HR-positive, HER2-negative breast cancer with a ki-67 index ≥ 20%.
[0203] In some embodiments of the present disclosure, the breast cancer is selected from lymph node-positive, HR-positive, HER2-negative breast cancer.
[0204] In some embodiments of the present disclosure, the breast cancer is selected from HR-positive, HER2-negative breast cancer with a high risk of recurrence.
[0205] In some embodiments of the present disclosure, the breast cancer is selected from HR-positive, HER2-negative early breast cancer.
[0206] In some embodiments of the present disclosure, the breast cancer is selected from breast cancer with positive lymph nodes and a Ki-67 index ≥ 20%.
[0207] In some embodiments of the present disclosure, the breast cancer is selected from breast cancer with a ki-67 index ≥ 20% and a high risk of recurrence.
[0208] In some embodiments of the present disclosure, the breast cancer is selected from early breast cancer with a Ki-67 index ≥ 20%.
[0209] In some embodiments of the present disclosure, the breast cancer is selected from lymph node-positive breast cancer with a high risk of recurrence.
[0210] In some embodiments of the present disclosure, the breast cancer is selected from early-stage lymph node-positive breast cancer.
[0211] In some embodiments of the present disclosure, the breast cancer is selected from early-stage breast cancer with a high risk of recurrence.
[0212] In some embodiments of the present disclosure, the breast cancer is selected from HR-positive, HER2-negative early breast cancer in patients who have received surgical treatment.
[0213] In some embodiments of the present disclosure, the breast cancer is selected from HR-positive, HER2-negative breast cancer with a Ki-67 index ≥ 20% in patients who have received surgical treatment.
[0214] In some embodiments of the present disclosure, the breast cancer is selected from lymph node-positive, HR-positive, HER2-negative breast cancer in patients who have received surgical treatment.
[0215] In some embodiments of the present disclosure, the breast cancer is selected from HR-positive, HER2-negative breast cancer with a high risk of recurrence in patients who have received surgical treatment.
[0216] In some embodiments of the present disclosure, the breast cancer is selected from breast cancer with positive lymph nodes and a Ki-67 index ≥ 20% in patients who have received surgical treatment.
[0217] In some embodiments of the present disclosure, the breast cancer is selected from lymph node-positive breast cancer with a high risk of recurrence in patients who have received surgical treatment.
[0218] In some embodiments of the present disclosure, the breast cancer is selected from lymph node-positive early-stage breast cancer in patients who have received surgical treatment.
[0219] In some embodiments of the present disclosure, the breast cancer is selected from breast cancer with a high risk of recurrence and a Ki-67 index ≥ 20% in patients who have received surgical treatment.
[0220] In some embodiments of the present disclosure, the breast cancer is selected from early breast cancer with a Ki-67 index ≥ 20% in patients who have received surgical treatment.
[0221] In some embodiments of the present disclosure, the breast cancer is selected from early-stage breast cancer with a high risk of recurrence in patients who have received surgical treatment.
[0222] In some embodiments of the present disclosure, the breast cancer is selected from HR-positive, HER2-negative, ki-67 index ≥ 20% breast cancer with a high risk of recurrence.
[0223] In some embodiments of the present disclosure, the breast cancer is selected from early breast cancer that is HR-positive, HER2-negative, and has a Ki-67 index ≥20%.
[0224] In some embodiments of the present disclosure, the breast cancer is selected from HR-positive, HER2-negative early-stage breast cancer with a high risk of recurrence.
[0225] In some embodiments of the present disclosure, the breast cancer is selected from breast cancer with positive lymph nodes, positive HR, negative HER2, and a Ki-67 index of ≥20%.
[0226] In some embodiments of the present disclosure, the breast cancer is selected from lymph node-positive, HR-positive, HER2-negative breast cancer with a high risk of recurrence.
[0227] In some embodiments of the present disclosure, the breast cancer is selected from lymph node-positive, HR-positive, HER2-negative early breast cancer.
[0228] In some embodiments of the present disclosure, the breast cancer is selected from early breast cancer with positive lymph nodes and a Ki-67 index ≥ 20%.
[0229] In some embodiments of the present disclosure, the breast cancer is selected from breast cancer with high risk of recurrence and positive lymph nodes and a Ki-67 index ≥ 20%.
[0230] In some embodiments of the present disclosure, the breast cancer is selected from early-stage breast cancer with a ki-67 index ≥ 20% and a high risk of recurrence.
[0231] In some embodiments of the present disclosure, the breast cancer is selected from lymph node-positive early-stage breast cancer with a high risk of recurrence.
[0232] In some embodiments of the present disclosure, the breast cancer is selected from HR-positive, HER2-negative, ki-67 index ≥ 20% breast cancer with a high risk of recurrence in patients who have received surgical treatment.
[0233] In some embodiments of the present disclosure, the breast cancer is selected from early-stage breast cancer that is HR-positive, HER2-negative, and has a Ki-67 index of ≥20% in patients who have received surgical treatment.
[0234] In some embodiments of the present disclosure, the breast cancer is selected from breast cancer with positive lymph nodes, HR positive, HER2 negative, and Ki-67 index ≥ 20% in patients who have received surgical treatment.
[0235] In some embodiments of the present disclosure, the breast cancer is selected from early breast cancer with positive lymph nodes and a Ki-67 index ≥ 20% in patients who have received surgical treatment.
[0236] In some embodiments of the present disclosure, the breast cancer is selected from breast cancer with high risk of recurrence, lymph node positive, Ki-67 index ≥ 20%, in patients who have received surgical treatment.
[0237] In some embodiments of the present disclosure, the breast cancer is selected from lymph node-positive early-stage breast cancer with a high risk of recurrence in patients who have received surgical treatment.
[0238] In some embodiments of the present disclosure, the breast cancer is selected from early-stage breast cancer with a high risk of recurrence and a Ki-67 index ≥ 20% in patients who have received surgical treatment.
[0239] In some embodiments of the present disclosure, the breast cancer is selected from HR-positive, HER2-negative early-stage breast cancer with a high risk of recurrence in patients who have received surgical treatment.
[0240] In some embodiments of the present disclosure, the breast cancer is selected from lymph node-positive, HR-positive, HER2-negative early breast cancer in patients who have received surgical treatment.
[0241] In some embodiments of the present disclosure, the breast cancer is selected from lymph node-positive, HR-positive, HER2-negative breast cancer with a high risk of recurrence in patients who have received surgical treatment.
[0242] In some embodiments of the present disclosure, the breast cancer is selected from breast cancer with high risk of recurrence and positive lymph nodes, positive HR, negative HER2, and a Ki-67 index of ≥20%.
[0243] In some embodiments of the present disclosure, the breast cancer is selected from early breast cancer with positive lymph nodes, positive HR, negative HER2 and a Ki-67 index of ≥20%.
[0244] In some embodiments of the present disclosure, the breast cancer is selected from lymph node-positive, HR-positive, HER2-negative early breast cancer with a high risk of recurrence.
[0245] In some embodiments of the present disclosure, the breast cancer is selected from early breast cancer with high risk of recurrence and positive lymph nodes and a Ki-67 index ≥ 20%.
[0246] In some embodiments of the present disclosure, the breast cancer is selected from early-stage breast cancer with a high risk of recurrence that is HR-positive, HER2-negative, and has a ki-67 index ≥ 20%.
[0247] In some embodiments of the present disclosure, the breast cancer is selected from breast cancer with a high risk of recurrence and lymph node positive, HR positive, HER2 negative, and a Ki-67 index ≥ 20% in patients who have received surgical treatment.
[0248] In some embodiments of the present disclosure, the breast cancer is selected from early breast cancer with positive lymph nodes, HR positive, HER2 negative, and Ki-67 index ≥ 20% in patients who have received surgical treatment.
[0249] In some embodiments of the present disclosure, the breast cancer is selected from early breast cancer with high risk of recurrence, positive lymph nodes, and a Ki-67 index ≥ 20% in patients who have received surgical treatment.
[0250] In some embodiments of the present disclosure, the breast cancer is selected from lymph node-positive, HR-positive, HER2-negative early breast cancer with a high risk of recurrence in patients who have received surgical treatment.
[0251] In some embodiments of the present disclosure, the breast cancer is selected from early breast cancer with high risk of recurrence and lymph node positive, HR positive, HER2 negative, and Ki-67 index ≥20%.
[0252] In some embodiments of the present disclosure, the breast cancer is selected from early-stage breast cancer with a high risk of recurrence that is HR-positive, HER2-negative, and has a ki-67 index of ≥20% in patients who have received surgical treatment.
[0253] In some embodiments of the present disclosure, the breast cancer is selected from early breast cancer with a high risk of recurrence and lymph node positive, HR positive, HER2 negative, and a Ki-67 index ≥ 20% in patients who have received surgical treatment.
[0254] In some embodiments of the present disclosure, the breast cancer is selected from postmenopausal or premenopausal / perimenopausal breast cancer. In some embodiments of the present disclosure, the breast cancer is breast cancer in patients who have undergone radical resection of breast cancer, or whose pathological examination confirmed that there is no residual invasive cancer and residual ductal carcinoma in situ or lobular carcinoma in situ at the resection margin after breast-conserving surgery, and there is no evidence of recurrence or distant metastasis after surgery.
[0255] In some embodiments of the present disclosure, the breast cancer is selected from postmenopausal or premenopausal / perimenopausal breast cancer in patients who have previously undergone bilateral oophorectomy.
[0256] In some embodiments of the present disclosure, the breast cancer is selected from postmenopausal breast cancer in patients aged ≥60 years.
[0257] In some embodiments of the present disclosure, the breast cancer is selected from postmenopausal breast cancer in patients aged <60 years and with a natural menopause period of ≥12 months.
[0258] In some embodiments of the present disclosure, the breast cancer is selected from premenopausal / perimenopausal breast cancer in a patient receiving LHRH agonist therapy.
[0259] In some embodiments of the present disclosure, the positive lymph node is axillary lymph node metastasis.
[0260] In some embodiments of the present disclosure, the positive lymph node refers to the presence of lymph node metastasis on the same side of the breast lesion.
[0261] In some embodiments of the present disclosure, the positive lymph node refers to the number of axillary lymph node metastases being ≥4.
[0262] In some embodiments of the present disclosure, the positive lymph node is 1-3 axillary lymph node metastases, and the pathological detection shows that the diameter of the primary tumor is ≥5 cm; or the number of axillary lymph node metastases is 1-3, and the primary tumor is histologically graded III; or the number of axillary lymph node metastases is 1-3, and there is residual invasive cancer in the primary breast lesion or the ipsilateral axillary lymph node after neoadjuvant treatment.
[0263] In some embodiments of the present disclosure, the breast cancer patient received neoadjuvant therapy before surgical treatment. In some embodiments of the present disclosure, the neoadjuvant therapy regimen includes the EC-T regimen (epirubicin, cyclophosphamide combined, sequentially with docetaxel), the TEC regimen (docetaxel, epirubicin combined with cyclophosphamide), the TC regimen (docetaxel combined with cyclophosphamide), and / or the TCb regimen (docetaxel combined with carboplatin, combined with trastuzumab and pertuzumab).
[0264] In some embodiments of the present disclosure, the breast cancer patient has received adjuvant treatment after surgical treatment and has not relapsed before implementing the method, combination therapy or use of the present disclosure.
[0265] In some embodiments of the present disclosure, the breast cancer patient has received adjuvant endocrine drug therapy after surgical treatment and before implementing the method, combination therapy or use of the present disclosure, and has not had a relapse.
[0266] In some embodiments of the present disclosure, the breast cancer patient has received neoadjuvant therapy after surgical treatment and has not relapsed before implementing the method, combination therapy or use of the present disclosure.
[0267] In some embodiments of the present disclosure, the breast cancer patient has received neoadjuvant treatment after surgical treatment and before implementing the method, combination therapy or use of the present disclosure, and has not relapsed. The neoadjuvant treatment regimen includes the EC-T regimen (epirerubicin, cyclophosphamide combined, followed by docetaxel), the TEC regimen (docetaxel, epirerubicin combined with cyclophosphamide), the TC regimen (docetaxel combined with cyclophosphamide) and / or the TCb regimen (docetaxel combined with carboplatin, combined with trastuzumab and pertuzumab).
[0268] In some embodiments of the present disclosure, the breast cancer patient has completed adjuvant therapy and / or neoadjuvant therapy in accordance with the diagnosis and treatment standards after surgical treatment and before implementing the method, combination therapy or use of the present disclosure, and the previous treatment for breast cancer must meet the following conditions at the same time: (1) the subject of neoadjuvant therapy must receive at least 4 cycles of treatment, and the chemotherapy regimen must include taxanes; (2) the time from radical breast surgery or breast-conserving surgery to randomization is no more than 14 months; (3) the last administration of adjuvant therapy is no less than 21 days from the randomization time; (4) the last administration of adjuvant radiotherapy is no less than 14 days from the randomization time; (5) after the last non-endocrine treatment (including surgery, radiotherapy, chemotherapy) and before randomization, the subject can receive endocrine therapy for a total of no more than 12 weeks (LHRH agonist time is not limited).
[0269] In some embodiments of the present disclosure, HR positivity includes estrogen receptor ER positivity and / or progesterone receptor PR positivity, which is defined as: the proportion of positively stained tumor cells in all tumor cells is ≥10%.
[0270] In some embodiments of the present disclosure, HER2 negativity is defined as: immunohistochemistry (IHC) testing showing HER2 as 0 / 1+; if the test shows 2+, fluorescence in situ hybridization (FISH) is required to confirm that it is negative, or only FISH testing is negative.
[0271] The "random time" described in the present disclosure refers to the time when the randomized subjects are assigned drugs.
[0272] As used herein, "adjuvant therapy" refers to the administration of one or more drugs to a patient following surgical resection of one or more cancerous tumors (where all detectable and resectable disease (e.g., cancer) has been cleared from the patient's body, but there remains a statistical risk of recurrence due to occult disease), with the goal of reducing the likelihood or severity of disease recurrence or delaying the onset of biological manifestations of disease recurrence.
[0273] The "Ki67 antigen" or simply "Ki67" as described in the present disclosure (also known as the antigen recognized by the monoclonal antibody Ki-67) refers to a nuclear protein encoded by the MKI67 gene that is expressed in all stages of the cell cycle other than the G0 phase and has been reported as an independent prognostic factor in early breast cancer (Dowsett et al. 2011). In HR+ breast cancer, patients with high Ki67 levels have been shown to have a higher rate of disease recurrence while receiving adjuvant endocrine therapy after surgery. In the BIG 1-98 study (Viale et al. 2008), patients who received letrozole with HR+ early breast cancer involving their axillary lymph nodes and low (≤11%) Ki67 baseline levels had a 93% 4-year disease-free survival, compared to 85% 4-year disease-free survival for patients with higher Ki67 values (>11%). Currently, there is no consensus on the precise baseline Ki67 level that distinguishes patients with a higher or lower risk of disease recurrence while receiving adjuvant endocrine therapy. However, the majority of the expert panel at the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 were prepared to accept a Ki67 threshold in the range of 20% to 29% (Vasconcelos et al. 2016) as an indication of a high-risk group suitable for adjuvant chemotherapy.
[0274] The active ingredients in the pharmaceutical combination of the present disclosure can be formulated independently, or partly or entirely thereof, with a pharmaceutically acceptable carrier and / or excipient. The pharmaceutical combination of the present disclosure may also include an additional therapeutic agent. In some embodiments of the present disclosure, the additional therapeutic agent may be a therapeutic agent known in the art for cancer, preferably a therapeutic agent for breast cancer.
[0275] In some embodiments of the present disclosure, the treatment cycle is 28 days.The amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof administered can be determined based on the severity of the disease, the response of the disease, any treatment-related toxicity, and the age and health status of the patient.
[0276] The compound of formula (I) or a pharmaceutically acceptable salt thereof can be administered by a variety of routes, including but not limited to the following: oral, parenteral, intraperitoneal, intravenous, intraarterial, transdermal, sublingual, intramuscular, rectal, transbuccal, intranasal, by inhalation, vaginal, intraocular, topical, subcutaneous, intrafatty, intraarticular, intraperitoneal and intrathecal. In a specific embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered orally.
[0277] In some embodiments of the present disclosure, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a continuous daily oral administration mode. The compound of formula (I) or a pharmaceutically acceptable salt thereof can be administered once or multiple times daily. In some embodiments of the present disclosure, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered once a day. The compound of formula (I) or a pharmaceutically acceptable salt thereof can also be administered in a single dose or multiple doses. In one embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered once a day in multiple doses.
[0278] In some embodiments of the present disclosure, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered once daily in multiple doses of an oral solid dosage form. In one embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered once daily in multiple doses.
[0279] The method of administration can be determined comprehensively based on the activity, toxicity and patient tolerance of the drug.
[0280] Compound of formula (I) or a pharmaceutically acceptable salt thereof
[0281] As used in the present disclosure, a pharmaceutically acceptable salt of a compound of formula (I) may be a maleate salt of a compound of formula (I) (eg, a monomaleate salt of a compound of formula (I)).
[0282] The dosages of the compound of formula (I) or its pharmaceutically acceptable salts referred to in the present disclosure are based on the mass of the molecule of the compound of formula (I), unless otherwise specified. For example, a dosage of 50 mg or 60 mg indicates a mass of 50 mg or 60 mg of the molecule of the compound of formula (I).
[0283] The compound of formula (I) or a pharmaceutically acceptable salt thereof used in the present disclosure can be prepared by methods in the prior art, for example, by referring to the method of WO2016141881.
[0284] Pharmaceutical composition of a compound of formula (I) or a pharmaceutically acceptable salt thereof
[0285] In some embodiments of the present disclosure, a single dose of the pharmaceutical composition of the compound of formula (I) or a pharmaceutically acceptable salt thereof may be 50 mg or 60 mg based on the compound of formula (I).
[0286] In some embodiments of the present disclosure, a single dose of the pharmaceutical composition of the compound of formula (I) or a pharmaceutically acceptable salt thereof is 60 mg.
[0287] The method of administration can be determined comprehensively based on the activity, toxicity and patient tolerance of the drug.
[0288] In some embodiments of the present disclosure, the pharmaceutical composition containing the compound of formula (I) or a pharmaceutically acceptable salt thereof further contains a pharmaceutically acceptable excipient. Pharmaceutically acceptable excipients include fillers, absorbents, wetting agents, binders, disintegrants, lubricants, and the like. In some embodiments of the present disclosure, the pharmaceutical composition includes but is not limited to preparations suitable for oral, parenteral, and topical administration; in some embodiments, the pharmaceutical composition is a preparation suitable for oral administration; in some embodiments, the pharmaceutical composition is a solid preparation suitable for oral administration; in some embodiments, the pharmaceutical composition includes but is not limited to tablets and capsules.
[0289] In some embodiments of the present disclosure, the pharmaceutical composition is a solid pharmaceutical composition. In some embodiments of the present disclosure, the pharmaceutical composition is a capsule. In some embodiments of the present disclosure, the pharmaceutical composition of the compound of formula (I) or a pharmaceutically acceptable salt thereof is a solid pharmaceutical composition of the compound of formula (I). In some embodiments of the present disclosure, the pharmaceutical composition of the compound of formula (I) or a pharmaceutically acceptable salt thereof is a capsule of the compound of formula (I).
[0290] The pharmaceutical compositions of the compounds of formula (I) or pharmaceutically acceptable salts thereof disclosed herein can be manufactured by methods well known in the art, such as conventional mixing, dissolving, granulating, making sugar-coated pills, grinding, emulsifying, freeze-drying, etc.
[0291] Solid oral compositions can be prepared by conventional mixing, filling, or tableting methods. For example, they can be prepared by mixing the active compound with a solid excipient, optionally grinding the resulting mixture, adding other suitable excipients as needed, and then granulating the mixture to obtain a tablet or dragee core. Suitable excipients include, but are not limited to, binders, diluents, disintegrants, lubricants, glidants, sweeteners, or flavoring agents.
[0292] Letrozole
[0293] As used in this disclosure, letrozole is chemically known as 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole, and has the following structural formula:
[0294] Pharmaceutical composition of letrozole
[0295] In some embodiments of the present disclosure, the pharmaceutical composition of letrozole further contains a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutically acceptable excipient includes a filler, an absorbent, a wetting agent, a binder, a diluent, a disintegrant, a lubricant, a glidant, a sweetener, or a flavoring agent.
[0296] In some embodiments of the present disclosure, the pharmaceutical composition is a solid pharmaceutical composition. In some embodiments of the present disclosure, the pharmaceutical composition is a tablet. In some embodiments of the present disclosure, the pharmaceutical composition is an oral tablet.
[0297] In some embodiments of the present disclosure, the single dose of the letrozole pharmaceutical composition is 2.5 mg.
[0298] Anastrozole
[0299] As used in this disclosure, the chemical name of anastrozole is a,a,a',a'-tetramethyl-5-(1H-1,2,4-triazole-1-methyl)-1,3-phenylenediacetonitrile, which has the following structural formula:
[0300] Pharmaceutical compositions of anastrozole
[0301] In some embodiments of the present disclosure, the pharmaceutical composition of anastrozole further contains a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutically acceptable excipient includes a filler, an absorbent, a wetting agent, a binder, a diluent, a disintegrant, a lubricant, a glidant, a sweetener, or a flavoring agent.
[0302] In some embodiments of the present disclosure, the pharmaceutical composition is a solid pharmaceutical composition. In some embodiments of the present disclosure, the pharmaceutical composition is a tablet. In some embodiments of the present disclosure, the pharmaceutical composition is an oral tablet.
[0303] In some embodiments of the present disclosure, a single dose of the anastrozole pharmaceutical composition is 1 mg.
[0304] Tamoxifen
[0305] As used in this disclosure, tamoxifen is chemically known as (Z)-2-[4-(1,2-diphenyl-1-butene)phenoxy]-N,N-dimethylethanamine, and has the following structural formula:
[0306] Pharmaceutical compositions of tamoxifen
[0307] In some embodiments of the present disclosure, the pharmaceutical composition of tamoxifen further contains a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutically acceptable excipient includes a filler, an absorbent, a wetting agent, a binder, a diluent, a disintegrant, a lubricant, a glidant, a sweetener, or a flavoring agent.
[0308] In some embodiments of the present disclosure, the pharmaceutical composition is a solid pharmaceutical composition. In some embodiments of the present disclosure, the pharmaceutical composition is a tablet. In some embodiments of the present disclosure, the pharmaceutical composition is an oral tablet.
[0309] In some embodiments of the present disclosure, a single dose of the tamoxifen pharmaceutical composition is 10 mg.
[0310] Administration
[0311] The following does not limit the administration mode of the combined pharmaceutical composition of the present disclosure.
[0312] The active ingredients in the combination pharmaceutical composition of the present disclosure can be administered individually, or some or all of them together, in various suitable routes, including but not limited to, oral or parenteral (via intravenous, intramuscular, topical or subcutaneous routes). In some embodiments of the present disclosure, the active ingredients in the combination pharmaceutical composition of the present disclosure can be administered individually, or some or all of them together orally.
[0313] The active ingredients in the combination pharmaceutical composition of the present invention can be each independently, or some or all of them together can be in suitable dosage forms, including but not limited to, tablets, lozenges, pills, capsules (such as hard capsules, soft capsules, enteric-coated capsules, microcapsules), elixirs, granules, syrups, injections (intramuscular, intravenous, intraperitoneal), granules, emulsions, suspensions, solutions, dispersions and sustained-release preparations for oral or parenteral administration.
[0314] Technical Effects
[0315] Generally, use of the above-described combination pharmaceutical compositions of the present disclosure will help:
[0316] (1) Produce a better therapeutic effect in reducing tumor growth or even eliminating tumors compared to administering either drug alone;
[0317] (2) provide for administration of a smaller amount of the drug than would be possible with either drug alone;
[0318] (3) provide a treatment that is well tolerated by patients and has fewer adverse effects and / or complications than either drug given alone;
[0319] (4) provide better disease control rates among treated patients;
[0320] (5) provide longer survival (e.g., median survival, progression-free survival, or overall survival) in treated patients;
[0321] (6) provide longer survival (e.g., median survival, progression-free survival, or overall survival) for treated patients compared to standard chemotherapy;
[0322] (7) provide a longer duration of disease remission (DOR); and / or
[0323] (8) Compared with the administration of any drug in the combination alone, the combination has good activity in treating tumors or proliferative diseases and exhibits a more excellent anti-tumor synergistic effect.
[0324] The "clinical benefits" of the combination drug composition disclosed herein include, but are not limited to: prolonged progression-free survival (PFS), prolonged overall survival (OS), improved objective response rate (ORR), improved disease control rate (DCR), reduced number and / or severity of adverse reactions, decreased distant metastasis rate and local control rate, etc. For example, the combination drug composition disclosed herein can significantly increase distant recurrence-free survival, prolong patient survival, and particularly prolong invasive cancer-free survival.
[0325] Definition and Description
[0326] As used herein, the term "combination pharmaceutical composition" refers to a combination of two or more active ingredients (administered as the respective active ingredients themselves, or as their respective pharmaceutically acceptable salts or esters, derivatives, prodrugs, or compositions) that are administered simultaneously or sequentially, and does not necessarily mean that the two or more active ingredients are contained in the same drug or formulation. The terms "combination pharmaceutical composition" and "drug combination" are used interchangeably herein.
[0327] The word "comprise" or "comprises" and its English variations such as comprises or comprising and their equivalents should be understood as open and non-exclusive, that is, "including but not limited to", meaning that in addition to the listed elements, components and steps, other unspecified elements, components and steps may also be included.
[0328] The term "patient" or "individual / subject" refers to a mammal, such as a primate (human, macaque, chimpanzee, etc.), a rodent (mice, rats, rabbits, etc.), a cat, a canine, etc., preferably a human. In some embodiments of the present disclosure, the patient and the individual are patients who have failed standard treatment or lack standard treatment.
[0329] The term "pharmaceutically acceptable" or "pharmaceutically usable" refers to a carrier, excipient or excipient used to prepare a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes that which is acceptable for use in human medicine.
[0330] The term "therapeutically effective amount" means the amount of a compound that, when administered to a human for treating a disease, is sufficient to effect such treatment.
[0331] The term "treating" means administering a compound or formulation of the present disclosure to improve, alleviate, or eliminate a disease or one or more symptoms associated with the disease, and includes: (i) inhibiting a disease or disease state, i.e., curbing or retarding its development; and (ii) relieving a disease or disease state, i.e., causing the disease or disease state to regress.
[0332] The term "prevention" means administering a compound or formulation of the present disclosure to prevent a disease or one or more symptoms associated with the disease, including preventing the disease or disease state from occurring in a mammal, particularly when such mammal is susceptible to the disease state but has not yet been diagnosed as having the disease state.
[0333] The use of alternatives (e.g., "or") should be understood to refer to any one, two, or any combination of the alternatives. The indefinite articles "a" or "an" used herein should be understood to mean "one or more" of any listed or enumerated components.
[0334] The term "pharmaceutically acceptable excipient" refers to an excipient that is non-irritating to organisms and does not impair the biological activity and properties of the active compound. Suitable excipients are well known to those skilled in the art and include, for example, carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, and the like.
[0335] The terms "administering" and "administering" refer to the physical introduction of a composition comprising a therapeutic agent into a subject using any of a variety of methods and delivery systems known to those skilled in the art. In certain embodiments, administration is oral administration.
[0336] The term "daily dose" refers to the dose administered to a patient daily. The term "daily dose" refers to the dose administered to a patient on a single day.
[0337] The term "single dose" or "unit preparation" refers to the smallest packaging unit of a drug containing a certain amount of active ingredient. For example, if a box of medicine contains seven capsules, each capsule is a single dose or unit preparation; for example, if a box of medicine contains seven tablets, each tablet is a single dose or unit preparation.
[0338] The term "multiple doses" consists of multiple single doses. As used herein, "combination" or "combined use" means that two or more active substances can be administered to an individual simultaneously, concurrently, or sequentially in any order, each as a single formulation.
[0339] The term "pharmaceutical composition" refers to a mixture of one or more active ingredients of the present disclosure or their pharmaceutical combination and pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate the administration of the compounds of the present disclosure or their pharmaceutical combination to an individual.
[0340] When referring to a dosing regimen, the terms "day," "daily," and the like refer to times within a calendar day, starting at midnight and ending at the following midnight.
[0341] The term "resection" refers to the surgical removal of malignant tissue characteristic of breast cancer from a patient's body. According to one embodiment, resection refers to the removal of malignant tissue such that the presence of remaining malignant tissue cannot be detected in the patient using available methods. According to another embodiment of the present invention, resection refers to the removal of breast cancer such that the presence of remaining breast cancer cannot be detected in the patient.
[0342] The term "radical mastectomy" refers to radical resection of breast cancer, including modified radical mastectomy, classic radical mastectomy, or extended radical mastectomy. The term "modified radical mastectomy" refers to a total mastectomy (sparing the pectoralis major / minor muscles) with axillary dissection. The term "classic radical mastectomy" refers to a total mastectomy (removing the pectoralis major / minor muscles) with axillary dissection. The term "extended radical mastectomy" refers to a total mastectomy (removing the pectoralis major / minor muscles) with axillary dissection and internal breast dissection. The term "early-stage" refers to cancer that may have spread to nearby lymph nodes but not to distant parts of the body.
[0343] The term “distant recurrence-free survival” refers to the time from the date of randomization to the first occurrence of distant recurrence or death from any cause.
[0344] The term “invasive cancer-free survival” was defined as the time from the date of randomization to the first occurrence of the following events: ipsilateral or contralateral recurrence of invasive breast cancer, regional or distant recurrence of invasive breast cancer, second primary malignancy in a non-breast area, or death from any cause.
[0345] The term “overall survival” refers to the time from the date of randomization to death from any cause.
[0346] The term "randomization day" refers to the time when randomized subjects are assigned their drug.
[0347] The term "high risk of recurrence" refers to the presence of lymph node metastasis in the axillary ipsilateral to the breast lesion as detected by postoperative pathological examination. The terms "high risk of recurrence" and "high risk" used in this disclosure are equivalent and interchangeable.
[0348] In this article, the terms "endocrine drugs" and "endocrine therapeutic drugs" are used interchangeably to refer to drugs used to treat endocrine diseases, including but not limited to aromatase inhibitors, estrogen receptor antagonists or pituitary gonadotropin-releasing hormone analogs.
[0349] In this document, unless the context clearly indicates otherwise, singular terms include plural referents and vice versa. Similarly, unless the context clearly indicates otherwise, the word "or" is intended to include "and" and vice versa.
[0350] Unless otherwise indicated, herein, the parameter values representing the amount of ingredients or physicochemical properties or reaction conditions, etc. should be understood as being modified by the term "about" in all cases. When the term "about" is used to describe the present application, the term "about" indicates that there is an error value, for example, it indicates a change within the range of ±5%, such as ±1% or ±0.1% of a particular value.
[0351] For the purposes of description and disclosure, all patents, patent applications, and other identified publications are expressly incorporated herein by reference. These publications are provided solely because their disclosure predates the filing date of the present application. All statements regarding the dates of these documents or the representations of their contents are based on information available to the applicant and do not constitute any admission as to the correctness of the dates of these documents or the contents of these documents. Furthermore, any citation of these publications herein does not constitute an admission that such publications constitute part of the common general knowledge in the art in any country. Example
[0352] The purpose of the following specific embodiments is to enable those skilled in the art to more clearly understand and implement the present disclosure. They should not be considered as limiting the scope of the present disclosure, but are merely exemplary descriptions and typical representatives of the present disclosure.
[0353] Experimental Example 1
[0354] This study adopted a randomized, double-blind, parallel-controlled, multicenter trial design. Eligible subjects were randomly divided into two groups at a ratio of 2:1 to receive either the compound of formula (I) capsules combined with endocrine therapy (experimental group) or the placebo capsules combined with endocrine therapy (control group).
[0355] 1.1 Inclusion Criteria:
[0356] Only those who meet all of the following inclusion criteria can be enrolled in this trial:
[0357] 1) The subjects voluntarily participated in this study, signed the informed consent form, and had good compliance;
[0358] 2) Age: 18 to 75 years old (at the time of signing the informed consent); ECOG PS score: 0 to 1;
[0359] 3) Postmenopausal or premenopausal / perimenopausal female patients;
[0360] 4) Received radical resection of breast cancer; or pathological examination confirmed that there was no residual invasive cancer and ductal carcinoma in situ at the resection margin after breast-conserving surgery
[0361] or residual lobular carcinoma in situ; and no evidence of recurrence or distant metastasis after surgery;
[0362] 5) Pathologically confirmed HR-positive, HER2-negative invasive breast cancer;
[0363] 6) Postoperative pathological examination indicates the presence of lymph node metastasis in the axillary ipsilateral to the breast lesion;
[0364] 7) The subjects have completed adjuvant and / or neoadjuvant chemotherapy according to the diagnosis and treatment standards before participating in this study;
[0365] 8) Major organ functions are good and meet the following criteria:
[0366] Routine blood tests must meet the following criteria: (no blood transfusion or use of hematopoietic stimulating factor drugs within 7 days before screening):
[0367] a) Hemoglobin (HB) ≥ 90 g / L;
[0368] b) Neutrophil absolute count (NEUT) ≥ 1.5 × 10 9 / L;
[0369] c) Platelet count (PLT) ≥100×10 9 / L.
[0370] Blood biochemistry tests must meet the following criteria (no corrective treatment within 7 days before screening):
[0371] a) Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN);
[0372] b) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 × ULN;
[0373] c) Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance (Ccr) ≥ 60 mL / min.
[0374] Coagulation function tests must meet the following criteria (without prior anticoagulant therapy):
[0375] a) Prothrombin time (PT) ≤ 1.5 × ULN;
[0376] b) activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;
[0377] c) International normalized ratio (INR) ≤ 1.5 × ULN.
[0378] Echocardiography assessment: left ventricular ejection fraction (LVEF) ≥ 50%.
[0379] 9) Female subjects of childbearing age should agree to use contraceptive measures (such as intrauterine devices, birth control pills or condoms) during the study and within 6 months after the end of the study; the serum pregnancy test should be negative within 7 days before study enrollment, and the subjects must be non-breastfeeding.
[0380] 1.2 Investigational Drugs
[0381] Capsules of compound of formula (I): Specification: 60 mg.
[0382] Letrozole tablets: Specification: 2.5mg.
[0383] Anastrozole tablets: Specification: 1mg.
[0384] Tamoxifen tablets: Specification: 10mg.
[0385] 1.3 Dosage regimen
[0386] (1) Compound of formula (I):
[0387] Capsules of the compound of formula (I): 120 mg, 150 mg, or 180 mg (based on the mass of the compound of formula (I)), taken orally on an empty stomach, once a day, for 28 consecutive days as one treatment cycle.
[0388] (2) Endocrine drugs: You can choose one of letrozole, anastrozole or tamoxifen. The specific dosage regimen is as follows:
[0389] Letrozole tablets: 2.5 mg orally, once a day, continuously taken, with each 28-day treatment cycle.
[0390] Anastrozole tablets: 1 mg orally, once a day, continuously taken, with each 28-day treatment cycle.
[0391] Tamoxifen tablets: 10 mg / time orally, twice a day, taken continuously, 28 days as a treatment cycle.
[0392] 1.4 Evaluation indicators and standards
[0393] Effectiveness evaluation indicators:
[0394] Invasive disease-free survival (IDFS) was defined as the time from the date of randomization to the first occurrence of the following events: ipsilateral or contralateral recurrence of invasive breast cancer, regional or distant recurrence of invasive breast cancer, second primary malignant tumor in non-breast sites, and death from any cause.
[0395] Distant relapse-free survival (DRFS) is the time from the date of randomization to the first occurrence of distant recurrence or death from any cause.
[0396] Overall survival (OS) is the time from the date of randomization to death from any cause.
[0397] Effectiveness evaluation criteria:
[0398] The Kaplan-Meier method was used to estimate median IDFS and its 95% confidence interval (CI), and Kaplan-Meier curves were plotted. Baseline risk was assumed to be different among strata. Based on this assumption, intergroup comparisons were performed using the stratified log-rank test, and intergroup hazard ratios (HRs) were estimated using the stratified Cox proportional hazards model. Median OS and its 95% CI were estimated using the Kaplan-Meier method, and Kaplan-Meier curves were plotted. Intergroup comparisons were performed using the stratified log-rank test, and intergroup HRs were estimated using the stratified Cox proportional hazards model.
[0399] Safety evaluation indicators:
[0400] The incidence and severity of adverse events (AEs), abnormal laboratory values, and serious adverse events (SAEs).
[0401] Safety evaluation standards:
[0402] The severity of adverse events was assessed using the NCI-CTC AE 5.0 criteria.
[0403] 1.5 Test results
[0404] 1.5.1 Security
[0405] The main adverse events were gastrointestinal reactions, and most TRAEs were grade 1-2, which were controllable after symptomatic treatment. No grade 4-5 TRAEs or treatment-related deaths were observed.
[0406] 1.5.2 Validity
[0407] The median follow-up time was 3-4 years. The invasive cancer-free survival (IDFS), distant recurrence-free survival (DRFS) and overall survival (OS) of the experimental group were all improved compared with those of the control group. For example, IDFS could be improved by more than 5%.
[0408] Experimental Example 2
[0409] This study was divided into two cohorts, Cohort 1 and Cohort 2. Both study drugs were a compound of formula (I) combined with an aromatase inhibitor. 30-60 subjects were enrolled in each cohort with HR-positive, HER2-negative locally advanced and / or metastatic breast cancer to evaluate the preliminary efficacy and safety of the compound of formula (I) combined with an aromatase inhibitor. The aromatase inhibitor was selected from letrozole or anastrozole, with 15-30 subjects enrolled in each cohort.
[0410] 2.1 Inclusion criteria:
[0411] 1) The subjects voluntarily participated in this study, signed the informed consent form, and had good compliance;
[0412] 2) Age: 18-75 years old (at the time of signing the informed consent); ECOG PS score: 0-1; expected survival time: more than 3 months;
[0413] 3) Postmenopausal or premenopausal / perimenopausal female patients;
[0414] 4) Patients with breast cancer diagnosed as HR-positive and HER2-negative by pathological examination;
[0415] 5) Subjects enrolled in Cohort 1 had recurrence or progression during or after completion of adjuvant endocrine therapy;
[0416] 6) completion of adjuvant endocrine therapy in cohort 1 was defined as discontinuation of therapy after at least 2 years of continuous treatment;
[0417] 7) Subjects enrolled in Cohort 2 had not previously received any systemic anti-tumor treatment for local lesion recurrence or metastatic disease;
[0418] 8) According to RECIST 1.1 criteria, at least one measurable lesion was confirmed;
[0419] 9) Major organ functions are good and meet the following criteria:
[0420] Routine blood test standards (no blood transfusion and no use of hematopoietic stimulating factor drugs within 7 days before screening):
[0421] a) Hemoglobin (HB) ≥ 100 g / L;
[0422] b) Neutrophil absolute count (NEUT) ≥ 1.5 × 10 9 / L;
[0423] c) Platelet count (PLT) ≥90×10 9 / L.
[0424] Biochemical examinations must meet the following criteria:
[0425] a) Total bilirubin (TBIL) ≤ 2.5 times the upper limit of normal (ULN);
[0426] b) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN. If accompanied by liver metastasis, ALT and AST ≤ 5 × ULN;
[0427] c) Serum creatinine (CR) ≤ 1.5 × ULN, or creatinine clearance (CCR) ≥ 60 ml / min.
[0428] Coagulation function tests must meet the following criteria:
[0429] Prothrombin time (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR) ≤ 1.5 × ULN (not receiving anticoagulant therapy);
[0430] Echocardiography assessment: left ventricular ejection fraction (LVEF) ≥ 50%;
[0431] 10) Female subjects of childbearing age must agree to use contraceptive measures (such as intrauterine devices, birth control pills or condoms) during the study and within 6 months after the end of the study; the serum pregnancy test must be negative within 7 days before study enrollment, and the subjects must be non-breastfeeding.
[0432] 2.2 Investigational Drugs
[0433] Capsules of the compound of formula (I): Specification: 60 mg.
[0434] Letrozole tablets: Specification: 2.5mg.
[0435] Anastrozole tablets: Specification: 1mg.
[0436] 2.3 Dosage regimen
[0437] (1) Compound of formula (I):
[0438] Capsules of the compound of formula (I): 180 mg (based on the mass of the compound of formula (I)), taken orally on an empty stomach, once a day, for 28 consecutive days as one treatment cycle.
[0439] (2) Aromatase inhibitors: Letrozole or anastrozole can be selected. The specific dosage regimen is as follows:
[0440] Letrozole tablets: 2.5 mg (based on the mass of letrozole) orally, once a day, continuously taken, with each 28-day treatment cycle, administered together with capsules of the compound of formula (I).
[0441] Anastrozole tablets: 1 mg (based on the mass of anastrozole) orally, once a day, continuously taken, with each 28-day treatment cycle. Administered together with capsules of the compound of formula (I).
[0442] 2.4 Evaluation Criteria
[0443] Effectiveness evaluation criteria: RECIST 1.1 criteria were used to determine the disease status.
[0444] Safety evaluation criteria: The NCI-CTC AE 5.0 standard was used to judge the severity of adverse events.
[0445] 2.5 Test results
[0446] 2.5.1 Security
[0447] A statistical analysis of the safety of 43 subjects showed that the main adverse events were gastrointestinal reactions, and most TRAEs were grade 1-2, which were controllable after symptomatic treatment. The overall incidence of grade 3 TRAEs was only 27.9%, and no grade 4-5 TRAEs or treatment-related deaths were observed.
[0448] 2.5.2 Validity
[0449] Of the 43 subjects, 38 were enrolled in Cohort 2, and the rest were subjects in Cohort 1. Thirty-five subjects (32 in Cohort 2 and 3 in Cohort 1) were evaluable for efficacy. Efficacy showed an ORR of 65.7% (23 / 35), of which 65.6% (21 / 32) in Cohort 2 had a response rate, consistent with the ORR of the overall population, and a clinical benefit rate (CBR) of 90.6% (29 / 32) in Cohort 2. The response rate of subjects in Cohort 1 was 66.7% (2 / 3), consistent with the ORR of the overall population, and a clinical benefit rate (CBR) of 100% (3 / 3) in Cohort 1. The proportion of 43 subjects with progression-free survival (DFS) of more than 3 years was greater than 75%.
[0450] Conclusion: The combined pharmaceutical composition disclosed herein can show good clinical benefits.
[0451] The following is a summary of representative subjects: Note: “NA” indicates not assessed; “*” indicates the percentage of tumor volume reduction; “--” indicates the tumor assessment point has not been reached.
[0452] Those skilled in the art will recognize that the scope of the present application is not limited to the various specific implementation modes and examples described above, but that various modifications, replacements, or recombinations can be made without departing from the spirit and concept of the present application, which all fall within the scope of protection of the present application.
Claims
1. A combination pharmaceutical composition for treating or preventing breast cancer in patients who have undergone surgical treatment, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and an endocrine therapy drug, 2. The combined pharmaceutical composition for use as claimed in claim 1, in, The endocrine therapy drug is selected from one or two of aromatase inhibitors, estrogen receptor antagonists or pituitary gonadotropin-releasing hormone analogs.
3. The combined pharmaceutical composition for use as claimed in claim 1 or 2, in, The endocrine therapy drug is selected from estrogen receptor antagonists, pituitary gonadotropin-releasing hormone analogs, a combination of an aromatase inhibitor and a pituitary gonadotropin-releasing hormone analog, or a combination of an estrogen receptor antagonist and a pituitary gonadotropin-releasing hormone analog.
4. The combined pharmaceutical composition for use as described in any one of claims 1 to 3, in, The aromatase inhibitor is selected from letrozole or anastrozole; The estrogen receptor antagonist is selected from tamoxifen; and / or The pituitary gonadotropin-releasing hormone analogue is selected from goserelin.
5. The combined pharmaceutical composition for use as described in any one of claims 1 to 4, in, The endocrine therapy drug is selected from letrozole, anastrozole, tamoxifen, a combination of letrozole and goserelin, a combination of anastrozole and goserelin, or a combination of tamoxifen and goserelin.
6. The combined pharmaceutical composition for use as described in any one of claims 1 to 5, in, The pharmaceutically acceptable salt of the compound of formula (I) is maleate, preferably monomaleate.
7. The combined pharmaceutical composition for use as described in any one of claims 1 to 6, in, The combination pharmaceutical composition contains a compound of formula (I) or a pharmaceutically acceptable salt thereof and an endocrine therapeutic drug in a mass ratio of 1:1 to 200:1, 10:1 to 200:1, 6:1 to 180:1, 6:1 to 90:1, 6:1 to 9:1, 48:1 to 72:1, 120:1 to 180:1, or any ratio within the above ranges, wherein the amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof is measured by the mass of the compound of formula (I), and the amount of the endocrine therapeutic drug is measured by the mass of the active ingredient therein.
8. The combination pharmaceutical composition according to any one of claims 1 to 6, in, The combination pharmaceutical composition contains 20-240 mg, 40-180 mg, 60-180 mg, 80-180 mg, 100-180 mg, 120-180 mg or 150-180 mg of the compound of formula (I) or its pharmaceutically acceptable salt, or a pharmaceutical composition thereof.
9. The combined pharmaceutical composition for use as claimed in claim 4, in, The combination pharmaceutical composition contains 2.5mg-12.5mg, 2.5mg-10mg, 2.5mg-7.5mg or 2.5mg-5mg of letrozole, or a pharmaceutical composition thereof; The combination pharmaceutical composition contains 1 mg-5 mg, 1 mg-4 mg, 1 mg-3 mg or 1 mg-2 mg of anastrozole, or a pharmaceutical composition thereof; and / or The combination pharmaceutical composition contains 10-40 mg or 20 mg-40 mg of tamoxifen, or a pharmaceutical composition thereof.
10. The combined pharmaceutical composition for use as claimed in claim 4, in, The combination pharmaceutical composition is a preparation suitable for administration in a single treatment cycle (e.g., 28 days), and the preparation contains: a total amount of 1680 mg to 5040 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof; and 70 mg to 140 mg of letrozole or a pharmaceutical composition thereof, wherein the amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is based on the mass of the compound of formula (I), and the amount of letrozole or a pharmaceutical composition thereof is based on the mass of letrozole; or The combination pharmaceutical composition is a preparation suitable for administration in a single treatment cycle (e.g., 28 days), and contains: a total amount of 1680 mg to 5040 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof; and a total amount of 28 mg to 140 mg of anaphylaxis. Anastrozole or a pharmaceutical composition thereof, wherein the amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is based on the mass of the compound of formula (I), and the amount of anastrozole or a pharmaceutical composition thereof is based on the mass of anastrozole.
11. The combined pharmaceutical composition for use as claimed in claim 4, in, The combination pharmaceutical composition is a preparation suitable for administration in a single treatment cycle (e.g., 28 days), and the preparation contains: a total amount of 1680 mg to 5040 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof; And a total amount of 560 mg-1120 mg of tamoxifen or a pharmaceutical composition thereof, wherein the amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is measured by the mass of the compound of formula (I), and the tamoxifen or the pharmaceutical composition thereof is measured by the mass of tamoxifen.
12. The combination pharmaceutical composition for use as claimed in any one of claims 8 to 11, wherein the pharmaceutical composition of the compound of formula (I) is a single dose or multiple doses; and / or The pharmaceutical composition of letrozole or the pharmaceutical composition of anastrozole, and the pharmaceutical composition of tamoxifen are in single dose or multiple doses.
13. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with an endocrine drug in the preparation of a drug for treating or preventing breast cancer in patients who have undergone surgical treatment, 14. A method for treating or preventing breast cancer in patients who have undergone surgical treatment, comprising administering to an individual in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and an endocrine therapy drug.
15. The combination pharmaceutical composition for use according to any one of claims 1 to 12, the use according to claim 13, or the method according to claim 14, in, The compound of formula (I) or a pharmaceutically acceptable salt thereof and an endocrine therapy drug are used for adjuvant treatment of breast cancer; The surgical treatment is selected from radical mastectomy or breast-conserving surgery; The breast cancer is selected from early breast cancer; The breast cancer is selected from HR-positive, HER2-negative breast cancer that has undergone surgical treatment; The breast cancer is selected from HR-positive, HER2-negative early breast cancer that has undergone surgical treatment; The breast cancer is selected from lymph node-positive, HR-positive, HER2-negative breast cancer that has undergone surgical treatment; The breast cancer is selected from early breast cancer with positive lymph nodes, positive HR and negative HER2 that has undergone surgical treatment; The breast cancer is selected from breast cancer with positive lymph nodes, positive HR, negative HER2, and ki-67 index ≥ 20%; or The breast cancer is selected from early breast cancer with high risk of recurrence that is lymph node positive, HR positive, HER2 negative, and ki-67 index ≥ 20%.
